


PERANAN LALUAN ISYARAT α 1NACHR-ERK DALAM
PEMBENTUKAN MATRIKS METALLOPROTEINASE
DALAM KALANGAN PEROKOK LELAKI DENGAN
SINDROM KORONARI AKUT

NAZIRAH BINTI SAMAH


UNIVERSITI KEBANGSAAN MALAYSIA

 UNIVERSITI KEBANGSAAN MALAYSIA <i>The National University of Malaysia</i>	UKM-SPKPPP-PT(PdP)-05-AK04-BO07	No. Semakan: 02	Tarikh Kuat Kuasa: 27/01/2026
	BORANG DAN SENARAI SEMAK PENYERAHAN TESIS/DISERTASI SELEPAS PEMBETULAN FORM AND CHECKLIST OF AMENDED THESIS/DISSERTATION SUBMISSION		

F. KELULUSAN DEKAN/PENGARAH / APPROVAL FROM DEAN/DIRECTOR			
Tandatangan:  Signature		Tarikh: 20 Februari 2026 Date	
Nama dan Cap Rasmi: Name and Official Stamp		PROFESOR DATIN DR MARINA MAT BAKI MD (UKM), MS ORL-HNS (UKM), PhD (UCL) Dekan Fakulti Perubatan Pakar Perunding Kanan ORL-HNS Universiti Kebangsaan Malaysia	
G. PERAKUAN TESIS/ DISERTASI SARJANA / DOKTOR FALSAFAH (CERTIFICATION OF MASTER'S / DOCTORAL THESIS / DISSERTATION)			
Nama penuh pengarang (Author's Full Name)	NAZIRAH BINTI SAMAH		
No. Pendaftaran Pelajar (Student's Registration No.)	P124809	Sesi Akademik (Academic Session)	SEMESTER 1 2025/2026
Tajuk Tesis / Disertasi (Thesis / Dissertation Title)	PERANAN LALUAN ISYARAT A1NACHR-ERK DALAM PEMBENTUKAN MATRIKS METALLOPROTEINASE DALAM KALANGAN PEROKOK LELAKI DENGAN SINDROM KORONARI AKUT		
Semua tesis/disertasi dan penerbitan berkaitan hasil penyelidikan pelajar adalah tertakluk kepada Dasar Harta Intelek Universiti Kebangsaan Malaysia. <i>All theses/ dissertations and publications relating to the research work of a student are subject to the Intellectual Property Policy of Universiti Kebangsaan Malaysia.</i> Saya mengaku bahawa tahap akses tesis/disertasi ini sebagai (*Tandakan ✓ dalam kotak bagi maklumat yang berkaitan; tandakan satu (1) kotak di bawah sahaja): <i>I hereby declare the level of access for this thesis/dissertation as follows (tick ✓ the relevant box below; tick only one option).</i>			
Pilihan Tahap Akses Access Level Selection		Tafsiran Tahap Akses Tesis/Disertasi Definition of Thesis/Dissertation Access Level	
☐	RAHSIA (CONFIDENTIAL)	Mengandungi maklumat rahsia sepertimana yang diperuntukan bawah Akta Rahsia Rasmi 1972. <i>Contains classified information as stipulated under the Official Secrets Act 1972.</i>	
☒	TERHAD (RESTRICTED)	Mengandungi maklumat yang hanya boleh diakses oleh pihak yang mempunyai kebenaran atau keperluan tertentu untuk mengetahuinya yang ditentukan oleh organisasi/ badan di mana penyelidikan dijalankan. <i>Contains information that may only be accessed by parties with specific authorization</i>	

 UNIVERSITI KEBANGSAAN MALAYSIA <i>The National University of Malaysia</i>	UKM-SPKPPP-PT(PdP)-05-AK04-BO07	No. Semakan: 02	Tarikh Kuat Kuasa: 27/01/2026
	BORANG DAN SENARAI SEMAK PENYERAHAN TESIS/DISERTASI SELEPAS PEMBETULAN FORM AND CHECKLIST OF AMENDED THESIS/DISSERTATION SUBMISSION		

		<i>or a defined need to know, as determined by the organization or body where the research is conducted.</i>
☐	AKSES TERBUKA (OPEN ACCESS)	Tesis/disertasi versi akhir dalam format PDF yang boleh diakses secara percuma secara dalam talian dan bebas dari isu hak cipta dan pelesenan <i>The final version of the thesis/dissertation in PDF format that is freely accessible online and free from copyright and licensing issues.</i> Kementerian Pendidikan Tinggi melalui surat bertarikh 27 Mac 2025 memutuskan bahawa kebenaran akses tesis / disertasi dalam borang serahan akses terbuka ditentukan oleh penyelia (bukan pelajar). <i>The Ministry of Higher Education, through a letter dated 27 March 2025, has decided that permission for thesis / dissertation access in the open access submission form shall be determined by the supervisor (not the student).</i>
☐	EMBARGO	Tempoh masa di mana akses kepada tesis/disertasi disekat (ditutup) selama dua (2) tahun atas sebab-sebab tertentu sebagai contoh kerahsiaan atau hak cipta. Tesis/disertasi akan berstatus akses terbuka selepas tamat tempoh <i>embargo</i>. <i>The period during which access to the thesis/dissertation is restricted for two (2) years due to specific reasons, such as confidentiality or copyright. The thesis/dissertation will be granted open-access status upon the expiry of the embargo period.</i>

PENGESAHAN PELAJAR (STUDENT VERIFICATION)		PENGESAHAN PENYELIA (SUPERVISOR VERIFICATION)	
 TANDATANGAN PELAJAR (STUDENT'S SIGNATURE)		 TANDATANGAN PENYELIA / Pengerusi JK SISWAZAH (SUPERVISOR'S / CHAIRPERSON SUPERVISION COMMITTEE SIGNATURE)	
Nama Pelajar (<i>Student name</i>): NAZIRAH BINTI SAMAH No. Pendaftaran Pelajar (<i>Student's Registration No.</i>) P124809 Tarikh: 13/02/2026 (<i>Date</i>)		Nama Penyelia / Pengerusi JK Siswazah : (<i>Supervisor's / Chairperson Supervision Committee Name</i>) Tarikh: 16/2/2026 (<i>Date</i>) 	

PERANAN LALUAN ISYARAT α 1NACHR-ERK DALAM PEMBENTUKAN
MATRIKS METALLOPROTEINASE DALAM KALANGAN PEROKOK
LELAKI DENGAN SINDROM KORONARI AKUT



TESIS YANG DIKEMUKAKAN UNTUK MEMPEROLEH
IJAZAH DOKTOR FALSAFAH

FAKULTI PERUBATAN
UNIVERSITI KEBANGSAAN MALAYSIA
KUALA LUMPUR


2026

PENGAKUAN

Saya akui karya ini adalah hasil kerja saya sendiri kecuali nukilan dan ringkasan yang tiap-tiap satunya telah saya jelaskan sumbernya.

16 Februari 2026

NAZIRAH BINTI SAMAH
P124809



PENGHARGAAN

Alhamdulillah, setinggi-tinggi kesyukuran dipanjatkan ke hadrat Ilahi atas rahmatNya yang tidak berpenghujung, saya telah berjaya menyempurnakan kajian ini dengan cemerlang. Kesihatan yang baik dan kekuatan diri yang dikurniakan telah membantu saya untuk mengharungi setiap langkah dalam usaha menyelesaikan kajian ini.

Pertama sekali, saya ingin melakar setulus penghargaan dan jutaan terima kasih kepada penyelia saya iaitu Profesor Madya Dr. Amilia Aminuddin atas bimbingan dan curahan ilmu yang berterusan kepada saya sepanjang penyelidikan ini. Tanpa sokongan beliau, saya mungkin tidak dapat menyelesaikan kajian ini dengan jayanya. Ucapan terima kasih turut ditujukan kepada penyelia bersama kajian ini, iaitu Profesor Madya Dr. Azizah Ugusman dan Dr. Adila A. Hamid atas perkongsian idea-idea bernas dengan penuh kesabaran dan ketelitian. Bantuan yang diberikan telah menjadi tunjang inspirasi sepanjang perjalanan penyelidikan ini.

Penghargaan yang ikhlas juga diberikan kepada Jabatan Fisiologi, Fakulti Perubatan UKM serta warga kakitangannya atas kemudahan makmal yang disediakan dan bimbingan yang diberikan. Bantuan tersebut turut melancarkan kerja-kerja makmal yang perlu saya lakukan dalam kajian ini. Tidak lupa juga kepada jabatan-jabatan praklinikal yang lain atas kebenaran untuk menggunakan peralatan mereka. Turut menyumbang jasa, doktor-doktor serta kakitangan dari Unit Forensik dan Unit Kardiologi, HCTM atas kerjasama mereka membantu pengumpulan sampel untuk kajian ini. Setinggi-tinggi penghargaan juga ditujukan kepada Profesor Dr. Zaleha Md Isa dan Encik Boekhtiar Borhanuddin atas bimbingan serta tunjuk ajar dalam menjalankan analisis statistik dan membantu saya menyempurnakan kajian ini.

Terima kasih juga kepada Kementerian Pendidikan Tinggi Malaysia atas peruntukan geran penyelidikan FRGS (kod projek: FRGS/1/2021/SKK0/UKM/03/1) yang telah banyak membantu membiayai bahan dan bekalan penyelidikan.

Selain itu, jutaan terima kasih juga buat rakan-rakan seperjuangan terutamanya Amanda, Asyraf, Ikmal dan Iffah yang menjadi tempat rujukan saya sepanjang penyelidikan ini. Kehadiran kalian turut menjadikan perjalanan ini lebih bermakna. Tidak dilupakan juga kepada pembantu penyelidik dan pelajar latihan industri iaitu Ubashini, Amir dan Chloe atas bantuan, dedikasi dan dorongan yang sangat berharga.

Penghargaan istimewa juga ditujukan kepada keluarga tercinta, khususnya mak dan ayah. Segala kepercayaan, pengorbanan, sokongan dan doa restu kalian adalah sumber kekuatan saya untuk menjayakan kajian ini. Seribu penghargaan juga saya ucapkan kepada suami saya, Muhammad Firdaus Bin Abdull Satar kerana menjadi sumber kekuatan saya dari awal pengajian hingga ke akhirnya. Akhir kata, terima kasih kepada semua pihak yang terlibat secara langsung atau tidak langsung dalam menjayakan kajian ini. Semoga segala usaha dan sokongan ini diberkati dan menjadi asbab kepada kejayaan, bukan sahaja untuk diri saya, tetapi untuk mereka yang akan mendapat manfaat daripada penyelidikan ini.

ABSTRAK

Sindrom koronari akut (ACS) merupakan manifestasi klinikal penyakit arteri koronari (CAD) yang kritikal berpunca daripada kepecahan plak aterosklerotik tidak stabil yang menyebabkan arteri koronari menjadi sempit dan mengurangkan bekalan darah ke miokardium. Merokok meningkatkan risiko ACS melalui pengaktifan enzim matriks metalloproteinase (MMP) yang mendegradasi lapisan fibrosa plak, manakala perencat tisu metalloproteinase (TIMP) berperanan menentang aktiviti tersebut. Walau bagaimanapun, mekanisme molekul yang mengaitkan tabiat merokok dengan peningkatan MMP dalam ACS masih belum difahami sepenuhnya. Kajian ini bertujuan mengkaji peranan laluan isyarat $\alpha 1nAChR$ –ERK terhadap pembentukan MMP dalam tisu plak aterosklerotik dan sel mononuklear darah periferi (PBMC) pesakit CAD. Sebanyak 41 tisu plak aterosklerotik diperoleh daripada subjek yang meninggal akibat CAD (26 perokok, 15 bukan perokok), manakala 180 subjek klinikal direkrut [$n = 30$ setiap kumpulan: ACS, sindrom koronari kronik (CCS) dan Kawalan; perokok dan bukan perokok]. Ekspresi gen $\alpha 1nAChR$, ERK 1/2 dan c-FOS dianalisis menggunakan RT-qPCR, manakala paras protein MMP-2, MMP-9 dan TIMP 3 ditentukan melalui ELISA. Skor Gensini diperoleh daripada penemuan angiogram, manakala parameter fungsi jantung [pecahan ejeksi ventrikel kiri (LVEF), halaju E, nisbah E/A, purata nisbah E/e', dan masa nyahpecutan gelombang E (EDT)] ditentukan melalui ekokardiografi. Keputusan menunjukkan ekspresi ERK 1/2 dan c-FOS adalah lebih tinggi (1.671 kali ganda dan 1.327 kali ganda) dalam tisu plak aterosklerotik perokok berbanding bukan perokok ($p < 0.05$), manakala $\alpha 1nAChR$ tidak berubah. Dalam PBMC, $\alpha 1nAChR$ adalah lebih tinggi (1.383 kali ganda, $p < 0.05$) dalam CCS perokok, manakala ERK 1/2 adalah lebih tinggi (1.355 kali ganda, $p < 0.001$) dalam ACS perokok berbanding CCS bukan perokok. Dalam kalangan perokok dan bukan perokok, MMP-9 dalam ACS dan CCS adalah lebih tinggi secara signifikan berbanding Kawalan ($p < 0.001$). Dalam CCS, MMP-9 dalam kalangan perokok adalah lebih tinggi berbanding bukan perokok (364.75 ± 1.2 vs 197.24 ± 1.2 ng/mL, $p = 0.036$). Manakala, TIMP 3 adalah lebih tinggi secara signifikan dalam kumpulan CCS perokok berbanding Kawalan perokok (26.98 ± 1.1 vs 16.94 ± 1.1 , $p < 0.001$). Seterusnya, MMP-9 berkorelasi positif dengan skor Gensini ($r = 0.556$, $p < 0.001$) dan negatif dengan LVEF ($r = -0.267$, $p < 0.001$) dalam kalangan perokok. Kesimpulannya, merokok mengaktifkan laluan isyarat $\alpha 1nAChR$ –ERK melalui peningkatan ERK 1/2 dalam tisu plak aterosklerotik serta peningkatan $\alpha 1nAChR$ dan ERK 1/2 dalam PBMC, mencerminkan tindak balas tempatan dan sistemik terhadap pendedahan nikotin. Pengaktifan laluan ini meningkatkan ekspresi MMP-9, seterusnya menyumbang kepada ketidakstabilan plak, peningkatan risiko perkembangan ACS, serta disfungsi jantung dalam pesakit CAD.

THE ROLE OF $\alpha 1$ nAChR-ERK 1/2 SIGNALING PATHWAY IN MATRIX METALLOPROTEINASE FORMATION AMONG MALE SMOKERS WITH ACUTE CORONARY SYNDROME

ABSTRACT

Acute coronary syndrome (ACS) is a critical clinical manifestation of coronary artery disease (CAD) resulting from the rupture of unstable atherosclerotic plaques that causes coronary arteries to narrow and reduced blood supply to the myocardium. Smoking increases the risk of ACS by activating matrix metalloproteinases (MMP), which degrade the fibrous cap of plaques, while tissue inhibitors of metalloproteinases (TIMP) counteract this activity. However, the molecular mechanisms linking smoking and increased MMP activity in ACS remain unclear. This study aimed to investigate the role of the $\alpha 1$ nAChR–ERK signaling pathway in MMP formation within atherosclerotic plaque tissues and peripheral blood mononuclear cells (PBMCs) of CAD patients. Forty-one atherosclerotic plaque samples were obtained from subjects who died due to CAD (26 smokers, 15 non-smokers), while 180 clinical subjects were recruited [n = 30 per group: ACS, chronic coronary syndrome (CCS), and controls; smokers and non-smokers]. Gene expression of $\alpha 1$ nAChR, ERK 1/2, and c-FOS was analyzed using RT-qPCR, while protein levels of MMP-2, MMP-9, and TIMP 3 were determined by ELISA. The Gensini score was derived from angiogram findings, whereas cardiac function parameters [left ventricular ejection fraction (LVEF), E velocity, E/A ratio, average E/e' ratio, and E-wave deceleration time (EDT)] were determined by echocardiography. Results showed higher expression of ERK 1/2 and c-FOS (1.671-fold and 1.327-fold) in atherosclerotic plaque tissues of smokers compared to non-smokers ($p < 0.05$), while $\alpha 1$ nAChR remained unchanged. In PBMCs, $\alpha 1$ nAChR expression was higher (1.383-fold, $p < 0.005$) in CCS smokers, and ERK 1/2 expression was higher (1.355-fold, $p < 0.001$) in ACS smokers compared to CCS non-smokers. Among smokers and non-smokers, MMP-9 in ACS and CCS were significantly higher compared to Controls ($p < 0.001$). In the CCS, MMP-9 was higher in smokers than in non-smokers (364.75 ± 1.2 vs 197.24 ± 1.2 ng/mL, $p = 0.036$). Meanwhile, TIMP 3 were significantly higher in smokers with CCS compared to smoker Controls (26.98 ± 1.1 vs 16.94 ± 1.1 , $p < 0.001$). Furthermore, MMP-9 showed a positive correlation with Gensini score ($r = 0.556$, $p < 0.001$) and a negative correlation with LVEF ($r = -0.267$, $p < 0.001$) among smokers. In conclusion, smoking activates the $\alpha 1$ nAChR–ERK signaling pathway through increased ERK 1/2 expression in atherosclerotic plaque tissue, as well as upregulation of $\alpha 1$ nAChR and ERK 1/2 in PBMCs, reflecting both local and systemic responses to nicotine exposure. This pathway activation enhances MMP-9 expression, contributing to plaque instability and increased risk of ACS progression, and cardiac dysfunction in CAD patients.

KANDUNGAN

	Halaman
PENGAKUAN	ii
PENGHARGAAN	iii
ABSTRAK	iv
ABSTRACT	v
KANDUNGAN	vi
SENARAI JADUAL	x
SENARAI ILUSTRASI	xiii
SENARAI SINGKATAN	xiv

BAB I	Pengenalan	
1.1	Pendahuluan	1
1.2	Permasalahan Kajian	6
1.3	Persoalan Kajian	6
1.4	Objektif Kajian	
1.4.1	Objektif Umum	7
1.4.2	Objektif Khusus	7
1.5	Hipotesis Kajian	7
BAB II	Kajian Perpustakaan	
2.1	Penyakit Kardiovaskular (CVD)	9
2.1.1	Definisi dan Jenis	9
2.1.2	Epidemiologi	10
2.2	Penyakit Koronari Arteri (CAD)	11
2.2.1	Definisi dan Jenis	11
2.2.2	Epidemiologi	13
2.2.3	Patofisiologi	14
2.3	Faktor Risiko CAD	17
2.3.1	Tabiat Merokok	17
2.3.2	Faktor Risiko Lain	20
2.4	Matrik Metalloproteinase (MMP) dan Perencat Tisu Metalloproteinase (TIMP)	22
2.4.1	Jenis Kumpulan	22
2.4.2	Proses Pengaktifan MMP	27

2.4.3	MMP-2 dan MMP-9	28
2.4.4	TIMP	29
2.4.5	TIMP 3	31
2.5	Patofisiologi Laluan Isyarat dalam Aterosklerosis dalam kalangan pesakit CAD	32
2.5.1	Laluan Isyarat nAChR, ERK 1/2, c-FOS	32
2.5.2	Pendekatan Sampel Kajian	37
2.6	Penilaian Keterukan CAD Menggunakan Skor Gensini	39
2.7	Penilaian Fungsi Jantung Pesakit CAD dengan Parameter Ekokardiografi	42
2.7.1	Pecahan Ejeksi Ventrikel Kiri (LVEF)	42
2.7.2	Halaju E, nisbah E/A, purata nisbah E/e' (Av E/e') dan masa nyahpecutan gelombang E (EDT)	44
BAB III	KAEDAH KAJIAN	
3.1	Pendahuluan	51
3.2	Kajian Tisu Plak Aterosklerotik Koronari	51
3.2.1	Pengenalan Kajian	51
3.2.2	Kriteria Penerimaan dan Pengecualian	54
3.2.3	Saiz Sampel Kajian	54
3.2.4	Pengumpulan dan Penyimpanan Sampel Plak Aterosklerotik	55
3.2.5	Analisis Ekspresi Gen α 1nAChR, ERK 1/2, dan c-FOS dalam tisu plak aterosklerotik	56
3.2.6	Analisis Paras Protein MMP-2, MMP-9, dan TIMP 3 dalam tisu plak aterosklerotik	64
3.2.7	Analisis Statistik	70
3.3	Kajian Sel Mononuklear Darah Periferi (PBMC) dan Serum	72
3.3.1	Pengenalan Kajian	72
3.3.2	Kriteria Penerimaan dan Pengecualian	74
3.3.3	Saiz Sampel Kajian	76
3.3.4	Pengumpulan, Pengasingan dan Penyimpanan PBMC dan Serum dari Sampel Darah	76
3.3.5	Analisis Ekspresi Gen α 1nAChR, ERK 1/2, dan c-FOS dalam PBMC	79
3.3.6	Analisis Paras Protein MMP-2, MMP-9, dan TIMP 3 dalam Serum	82
3.3.7	Analisis Statistik	87
3.4	Hubungkait Skor Gensini dan Paras Protein MMP-2, MMP-9 dan TIMP 3	88
3.5	Hubungkait Parameter Ekokardiografi dan Paras Protein MMP-2, MMP-9 dan TIMP 3	91

BAB IV PENGENALPASTIAN CIRI-CIRI DEMOGRAFI DAN KLINIKAL SUBJEK, ANALISIS GEN DAN PROTEIN SASARAN DALAM TISU PLAK ATEROSKLEROTIK KORONARI

4.1	Pengenalan	93
4.2	Hasil Kajian	94
4.2.1	Ciri-ciri Demografi dan Klinikal Subjek	94
4.2.2	Gambar Tisu Plak Aterosklerotik di dalam Arteri Koronari	96
4.2.3	Analisis Ekspresi Gen $\alpha 1nAChR$, ERK 1/2, dan c-FOS dalam tisu plak aterosklerotik	96
4.2.4	Analisis Paras Protein MMP-2, MMP-9, dan TIMP 3 dalam tisu plak aterosklerotik	98
4.3	Perbincangan	99

BAB V PENGENALPASTIAN CIRI-CIRI DEMOGRAFI DAN KLINIKAL PESAKIT, ANALISIS GEN DAN PROTEIN SASARAN DALAM PBMC DAN SERUM, PERHUBUNG-KAITAN ANTARA PROTEIN SASARAN DENGAN SKOR GENSINI DAN PARAMETER KARDIOGRAFI

5.1	Pengenalan	104
5.2	Hasil Kajian	105
5.2.1	Ciri-ciri Demografi, Klinikal dan Profil Darah Pesakit	105
5.2.2	Analisis Ekspresi Gen $\alpha 1nAChR$, ERK 1/2, dan c-FOS dalam PBMC	114
5.2.3	Analisis Paras Protein MMP-2, MMP-9, dan TIMP 3 dalam serum	118
5.2.4	Perhubungkaitan antara Paras Protein Sasaran MMP-2, MMP-9 dan TIMP 3 dengan Tahap Keterukan Plak Aterosklerotik (Skor Gensini)	123
5.2.5	Perhubungkaitan antara Paras Protein Sasaran MMP-2, MMP-9 dan TIMP 3 dengan Parameter Ekokardiografi (LVEF, E, E/A, Av E/e' dan EDT)	129
5.3	Perbincangan	153
5.3.1	Ekspresi Gen Sasaran $\alpha 1nAChR$, ERK 1/2, dan c-FOS dalam PBMC	153
5.3.2	Paras Protein Sasaran MMP-2, MMP-9, dan TIMP 3 dalam serum	159
5.3.3	Perhubungkaitan antara Paras Protein Sasaran MMP-2, MMP-9 dan TIMP 3 dengan Tahap Keterukan Plak Aterosklerotik (Skor Gensini)	164
5.3.4	Perhubungkaitan antara Paras Protein Sasaran MMP-2, MMP-9 dan TIMP 3 dengan Parameter Ekokardiografi (LVEF, E, E/A, Av E/e' dan EDT)	168

BAB VI KESIMPULAN DAN CADANGAN

6.1	Kesimpulan	178
6.2	Limitasi	181
6.3	Cadangan	181

RUJUKAN		183
----------------	--	-----

LAMPIRAN

Lampiran A	Surat Kelulusan Etika Menjalankan Penyelidikan	227
Lampiran B	Borang Maklumat Penyelidikan (Kajian Tisu Plak Aterosklerotik)	229
Lampiran C	Borang Persetujuan Pesakit (Kajian Tisu Plak Aterosklerotik)	231
Lampiran D	Borang Maklumat Penyelidikan (Kajian PBMC dan Serum)	232
Lampiran E	Borang Persetujuan Pesakit (Kajian PBMC dan Serum)	234
Lampiran F	Senarai Pembentangan	235
Lampiran G	Senarai Penerbitan Jurnal	238
Lampiran H	Senarai Anugerah	243

SENARAI JADUAL


No. Jadual		Halaman
Jadual 2.1	Jenis kumpulan MMP berdasarkan substrat	24
Jadual 2.2	Struktur domain pelbagai MMP	25
Jadual 3.1	Kriteria penerimaan dan pengecualian subjek	54
Jadual 3.2	Senarai primer gen sasaran	60
Jadual 3.3	Campuran RNA-primer	61
Jadual 3.4	Campuran sintesis cDNA	62
Jadual 3.5	Komponen campuran induk (<i>master mix</i>)	62
Jadual 3.6	Protokol tindak balas qPCR	63
Jadual 3.7	Penyediaan larutan piawai BCA	65
Jadual 3.8	Kriteria penerimaan dan pengecualian subjek	74
Jadual 3.9	Tahap stenosis dan skor	88
Jadual 3.10	Salur arteri koronari dan faktor pendaraban	89
Jadual 4.1	Ciri-ciri demografi dan klinikal subjek	95
Jadual 4.2	Nilai kali ganda perubahan ekspresi gen dalam kumpulan perokok dan bukan perokok	97
Jadual 4.3	Nilai paras protein dalam kumpulan perokok dan bukan perokok	98
Jadual 5.1	Ciri-ciri demografi dan klinikal subjek	106
Jadual 5.2	Profil darah pesakit	110
Jadual 5.3	Penggunaan ubat-ubatan berkaitan penyakit kardiovaskular	113
Jadual 5.4	Nilai kali ganda perubahan ekspresi gen dalam sel PBMC kumpulan ACS dan CCS mengikut status merokok, sebelum dan selepas pelarasan kovariat	116
Jadual 5.5	Nilai purata paras protein dalam serum kumpulan ACS, CCS dan Kawalan mengikut status merokok, sebelum dan selepas pelarasan kovariat	121

Jadual 5.6	Skor gensini dalam kumpulan ACS, CCS dan Kawalan	124
Jadual 5.7	Hubungan antara penanda biologi dan skor gensini dalam kalangan perokok	126
Jadual 5.8	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap skor gensini dalam kalangan perokok	126
Jadual 5.9	Hubungan antara penanda biologi dan skor gensini dalam kalangan bukan perokok	127
Jadual 5.10	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap skor gensini dalam kalangan bukan perokok	128
Jadual 5.11	Nilai purata LVEF dalam kumpulan ACS, CCS dan Kawalan	130
Jadual 5.12	Hubungan antara penanda biologi dan LVEF dalam kalangan perokok	132
Jadual 5.13	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap LVEF dalam kalangan perokok	132
Jadual 5.14	Hubungan antara penanda biologi dan LVEF dalam kalangan bukan perokok	133
Jadual 5.15	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap LVEF dalam kalangan bukan perokok	133
Jadual 5.16	Nilai purata halaju E dalam kumpulan ACS, CCS dan Kawalan	135
Jadual 5.17	Hubungan antara penanda biologi dan halaju E dalam kalangan perokok	136
Jadual 5.18	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap halaju E dalam kalangan perokok	137
Jadual 5.19	Hubungan antara penanda biologi dan halaju E dalam kalangan bukan perokok	138
Jadual 5.20	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap halaju E dalam kalangan bukan perokok	138
Jadual 5.21	Nilai purata nisbah E/A dalam kumpulan ACS, CCS dan Kawalan	140
Jadual 5.22	Hubungan antara penanda biologi dan nisbah E/A dalam kalangan perokok	142
Jadual 5.23	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap nisbah E/A dalam kalangan perokok	142
Jadual 5.24	Hubungan antara penanda biologi dan nisbah E/A dalam kalangan bukan perokok	143

Jadual 5.25	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap nisbah E/A dalam kalangan bukan perokok	143
Jadual 5.26	Nilai purata $Av E/e'$ dalam kumpulan ACS, CCS dan Kawalan	145
Jadual 5.27	Hubungan antara penanda biologi dan $Av E/e'$ dalam kalangan perokok	146
Jadual 5.28	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap $Av E/e'$ dalam kalangan perokok	147
Jadual 5.29	Hubungan antara penanda biologi dan $Av E/e'$ dalam kalangan bukan perokok	148
Jadual 5.30	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap $Av E/e'$ dalam kalangan bukan perokok	148
Jadual 5.31	Nilai purata EDT dalam kumpulan ACS, CCS dan Kawalan	150
Jadual 5.32	Hubungan antara penanda biologi dan EDT dalam kalangan perokok	151
Jadual 5.33	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap EDT dalam kalangan perokok	151
Jadual 5.34	Hubungan antara penanda biologi dan EDT dalam kalangan bukan perokok	152
Jadual 5.35	Data analisis regresi linear dan hierarki bagi penanda biologi terhadap EDT dalam kalangan bukan perokok	152

SENARAI ILUSTRASI

No. Rajah	Halaman
Rajah 2.1 Mekanisme perencatan TIMP terhadap MMP	30
Rajah 3.1 Carta aliran kajian	53
Rajah 3.2 Pencairan bersiri untuk penyediaan larutan piawai rujukan protein	68
Rajah 3.3 Carta aliran kajian	73
Rajah 3.4 Kaedah pengasingan PBMC dari darah periferi	78
Rajah 3.5 Pencairan bersiri untuk penyediaan larutan piawai rujukan protein	85
Rajah 4.1 Keratan rentas arteri koronari	96
Rajah 6.1 Cadangan mekanisme kesan merokok terhadap pengaktifan laluan isyarat $\alpha 1$ nAChR-ERK	180



SENARAI SINGKATAN

%	peratus
$\Delta\Delta CT$	kitaran ambang
$^{\circ}C$	darjah celcius
μL	mikro liter
$\alpha 1nAChR$	reseptor nikotinik asetilkolina alfa-1
$\alpha 1-AAV$	vektor virus berkaitan adenon alfa-1
$\alpha 3\beta 1$ -integrin	alfa-3 beta-1 integrin
ACS	sindrom koronari akut
ADAM	disintegrin dan metalloproteinase
ADAMTS	disintegrin dan metalloproteinase dengan motif trombospondin
AGTRI/2	reseptor angiotensin II jenis 1
ATF	faktor transkripsi pengaktif
ANOVA	analisis varians
ANCOVA	analisis kovarians
AP-1	protein pengaktif-1
Apo E	apolipoprotein E
$Av E/e'$	purata nisbah halaju pengisian awal kepada halaju anulus mitral diastolik awal
BATF	protein mirip ATF yang mengandungi domain <i>zipper leucine</i>
BCA	asai asid bikinkoninik
CAD	penyakit arteri koronari
CCS	sindrom koronari kronik
CD63	sel kluster pembezaan 63
CeVD	penyakit serebrovaskular
c-FOS	protein selular FOS
c-JUN	protein selular JUN
CHD	penyakit jantung kongenital
cm	sentimeter
CT	nilai kitaran ambang

CVD	penyakit kardiovaskular
DALYS	<i>disability-adjusted life years</i>
DM	diabetes mellitus
DNA	asid deoksiribonukleik
dNTP	deoksinukleosida trifostat
E	halaju pengisian awal diastolik
E/A	nisbah halaju pengisian awal mitral kepada halaju pengisian atrial
ECG	elektrokardiogram
ECM	matriks ekstraselular
EDT	masa nyahpecutan gelombang E
EDTA	tiub mengandungi asid etilenediamintetraasetik
EFEMP1	protein matriks ekstraselular menyerupai fibulin dengan domain EGF1
ELISA	asai imunosorben pautan enzim
ERK 1/2	kinase terkawal isyarat ekstraselular 1 dan 2
ET-1	endotelin-1
g	gram
GENLIN	model linear umum dengan pautan log gamma
GLM	model linear umum
Hs-CRP	protein C-reaktif berkepekatan tinggi
HRP	<i>horseradish peroxidase</i>
Hz	hertz (unit frekuensi)
ICAM-1	molekul lekatan antara sel-1
IHD	penyakit jantung iskemik
IL- β	interleukin beta
JDP2	protein pengdimeran Jun 2
K ⁺	ion kalium
kDa	kilodalton (unit jisim molekul)
LA	atrium kiri
LAD	arteri menurun anterior kiri
LAP	tekanan atrium kiri
LCx	arteri sirkumfleksi kiri

LBBB	sekatan berkas kiri
LDL-C	kolesterol lipoprotein berketumpatan rendah
LRP-1	protein berkaitan reseptor lipoprotein berketumpatan rendah 1
LV	ventrikel kiri
LVEF	pecahan ejeksi ventrikel kiri
LVDF	gangguan fungsi diastolik ventrikel kiri
LVFP	tekanan pengisian ventrikel kiri
MAPK	protein kinase diaktifkan mitogen
MI	infark miokardium
MINOCA	infark miokardium dengan arteri koronari tidak tersumbat
MMP-2	matriks metalloproteinase-2
MMP-9	matriks metalloproteinase-9
M-MuLV	virus Moloney <i>Murine Leukemia</i>
m/s	meter per saat
mg	miligram
mL	mililiter
MVD	penyakit pelbagai salur
Na ⁺	ion natrium
NFATc1	faktor nuklear sel T teraktif 1
nm	nanometer
NO	nikrik oksida
NCVD-ACS	pangkalan Data Penyakit Kardiovaskular Kebangsaan Malaysia-Sindrom Koronari Akut
NSTEMI	infark miokardium tanpa peningkatan segmen ST
O ₂ ⁻	superoksida
OD	ketumpatan optik
ONOO ⁻	peroksinitrit
Oligo d(T)	oligo deoksitiamina
OxLDL	lipoprotein berketumpatan rendah teroksida
PAD	penyakit arteri perifer
PBMC	sel mononuklear darah periferi
PBS	larutan penimbal fosfat
PCI	intervensi koronari perkutaneus

PDA	arteri menurun posterior
pH	unit keasidan/kealkalian larutan
p38MAPK	protein kinase diaktifkan mitogen p38
P13K/Akt	fosfoinositida 3-kinase/protein kinase B
PMI	infark miokardium periprosedure
RANK	reseptor pengaktif faktor nuklear- κ B
RHD	penyakit jantung reumatik
RNA	asid ribonukleik
RT-qPCR	tindak balas berantai polimerase kuantitatif transkripsi sonsang
SST	tiub pemisah serun
STEMI	infark miokardium dengan peningkatan segmen ST
TCFA	<i>thin cap fibroatheroma</i>
TIA	serangan iskemia sementara
TIMP 3	perencat tisu metalloproteinase 3
TNF α	faktor nekrosis tumor-alfa
UA	angina tidak stabil
VCAM-1	molekul lekatan sel vaskular
VEGFR	faktor pertumbuhan vaskular endotelium
VSMC	sel otot licin vaskular

BAB I

PENGENALAN

1.1 PENDAHULUAN

Penyakit kardiovaskular (CVD) adalah penyumbang utama kepada kematian dan morbiditi global. Sebanyak 20.5 juta kematian yang merangkumi satu pertiga daripada semua kematian global pada tahun 2021 adalah disebabkan oleh CVD (Lindstrom et al. 2022). Dalam kalangan jenis-jenis penyakit CVD, penyakit jantung iskemik (IHD) adalah yang paling berleluasa (Roth et al. 2017). Di Malaysia, statistik oleh Jabatan Perangkaan Malaysia pada tahun 2023 menunjukkan IHD adalah penyebab utama kematian pada tahun 2022, iaitu sebanyak 20,322 kematian atau 16.1% telah direkodkan (Jabatan Perangkaan Malaysia 2023). Dianggarkan bahawa pada tahun 2050, IHD akan menjadi penyumbang terbesar kepada beban kematian CVD yang diselaraskan umur, iaitu 416 kematian bagi setiap 100,000 penduduk di negara asia tengah (Goh et al. 2024).

IHD atau turut dikenali sebagai penyakit arteri koronari (CAD) adalah penyakit kekurangan bekalan darah dan oksigen kepada sel otot jantung akibat pembentukan plak di dalam salur arteri koronari (Shahjehan et al. 2024). Proses patofisiologi utama yang membawa kepada CAD ialah aterosklerosis, iaitu penyakit radang arteri yang dikaitkan dengan pemendapan lipid dan perubahan metabolik akibat pelbagai faktor (Ambrose & Singh 2015; Falk et al. 2013; Hanson et al. 2013). Terdapat dua klasifikasi CAD iaitu sindrom koronari akut (ACS) dan sindrom koronari kronik (CCS). ACS adalah manifestasi klinikal CAD yang paling kritikal kerana pembentukan plak yang tidak stabil dan terjadinya kepecahan plak aterosklerotik. Kepecahan plak ini mengakibatkan pembentukan trombus yang akan

menyekat atau mengurangi aliran darah ke otot jantung secara mendadak (Kitulwatte & Pollanen 2015). ACS diklasifikasikan kepada tiga kategori utama, iaitu infark miokardium dengan peningkatan segmen ST (STEMI), infark miokardium tanpa peningkatan segmen ST (NSTEMI), dan angina tidak stabil (UA). Kesemua keadaan ini berpotensi menyebabkan komplikasi serius, termasuklah serangan jantung, kegagalan fungsi jantung, dan kematian mengejut sekiranya tidak dirawat dengan segera (Kementerian Kesihatan Malaysia 2011). Menurut laporan tahunan pendaftaran Pangkalan Data Penyakit Kardiovaskular Kebangsaan Malaysia-Sindrom Koronari Akut (NCVD-ACS), terdapat 15,162 pesakit ACS telah dimasukkan di hospital pada tahun 2020-2021. Daripada jumlah itu, 50.3% pesakit didiagnosis dengan STEMI, 30.4% adalah NSTEMI, dan 19.3% adalah UA. Kebanyakan pesakit adalah lelaki (79.4%) dan muda dengan purata umur semasa kemasukan adalah 58.5 tahun (Wan Ahmad 2024).

Terdapat beberapa faktor risiko yang menyumbang kepada perkembangan ACS termasuk hipertensi, hiperkolesterolemia, diabetes mellitus, obesiti, gaya hidup tidak sihat, dan sejarah keluarga penyakit jantung (American Heart Association 2024). Walau bagaimanapun, salah satu faktor risiko yang paling signifikan dan boleh diubah untuk ACS adalah merokok. Kajian menunjukkan bahawa perokok mempunyai risiko hampir dua kali ganda lebih tinggi untuk mengalami ACS berbanding bukan perokok (Banks et al. 2019). Risiko ini meningkat dengan bilangan rokok yang dihisap setiap hari dan berkurang dalam kalangan bekas perokok (Banks et al. 2019). Merokok menyumbang kepada perkembangan dan kemajuan aterosklerosis, melalui disfungsi endotelium, peningkatan tekanan oksidatif, dan keradangan arteri (Addissouky et al. 2024; Hahad et al. 2023). Merokok juga mengurangkan ketahanan plak aterosklerotik dengan merosakkan lapisan fibrosa, yang berfungsi sebagai pelindung matriks ekstraselular (ECM) di salur arteri koronari. Satu kajian sistematik oleh Aminuddin et al. (2023) mendapati bahawa merokok meningkatkan degradasi lapisan fibrosa tersebut dengan meningkatkan aktiviti enzim matriks metalloproteinase (MMP). MMP adalah satu keluarga enzim endopeptidase yang bergantung kepada zink dan mempunyai aktiviti proteolitik terhadap ECM (Hey & Linder 2024). Enzim-enzim ini akan merosakkan kolagen dan komponen struktur lain dalam ECM, seterusnya mengakibatkan penipisan dan kerosakan pada lapisan fibrosa itu. Perubahan

patofisiologi ini mempercepat pembentukan plak aterosklerotik yang tidak stabil dan meningkatkan risiko plak untuk pecah, satu kejadian utama yang membawa kepada ACS (Naghavi et al. 2003; Teresa et al. 2023).

Terdapat beberapa jenis MMP yang berkait rapat dengan ketidakstabilan plak aterosklerotik, antaranya ialah MMP-2 dan MMP-9. MMP-2 atau juga dikenali enzim gelatinase A yang secara khususnya mengurai kolagen jenis IV, laminin dan elastin dalam ECM (Sanyal et al. 2022; Wolosowicz et al. 2024). Penguraian ini memberi kesan kepada pengubahsuaian vaskular dan angiogenesis (Salajeghah 2016). Aktiviti MMP-2 juga mengaktifkan MMP yang lain, termasuklah MMP-9, dan meningkatkan lagi kerosakan ECM serta ketidakstabilan plak. MMP-9 juga dikenali sebagai enzim gelatinase B, secara khususnya mengurai kolagen jenis I dan III iaitu kolagen penting untuk mengekalkan integriti struktur lapisan fibrosa yang melindungi plak aterosklerotik. MMP-9 dilepaskan oleh sel-sel makrofaj dan neutrofil ke lapisan serat plak dan meningkatkan keradangan dan pemecahan ECM (Newby 2016). Pemecahan ECM dalam lapisan fibrosa membawa kepada pendedahan teras lipid trombogenik dan pembentukan trombus, seterusnya, menyebabkan ACS. Kajian yang terdahulu mendapati bahawa kedua-dua MMP-2 dan MMP-9 meningkat dalam pesakit ACS dan dianggap sebagai penanda biologi ketidakstabilan dan kepecahan plak aterosklerotik (Ezhov et al. 2019; Funayama et al. 2021). Ini menunjukkan tahap MMP yang tinggi mencerminkan beban aterosklerosis yang lebih besar dan berpotensi untuk menilai keterukan CAD (Bräuninger et al. 2023; Marynenko et al. 2022). Skor Gensini, iaitu alat ukuran untuk menilai tahap keterukan penyakit CAD dengan mengkuantifikasi tahap dan lokasi stenosis arteri telah digunakan dalam kajian oleh Yu et al. (2012). Dalam kajian ini, mereka mendapati terdapat korelasi yang signifikan antara tahap MMP-2 dan MMP-9 yang meningkat dan skor Gensini yang lebih tinggi, mencadangkan bahawa peningkatan aktiviti MMP dikaitkan dengan kecederaan arteri koronari yang lebih teruk (Yu et al. 2012).

Selain itu, MMP juga dikaitkan dengan pengubahsuaian dan kekejangan fungsi ventrikel kiri (LV), iaitu tanda penting dalam pesakit ACS (Esmailzadeh et al. 2013). Kajian telah menunjukkan bahawa kepekatan MMP-9 yang lebih tinggi berkorelasi dengan peningkatan volum LV dan pengurangan pecahan ejeksi (EF), seperti yang

diperhatikan melalui pengukuran ekokardiografi (Lahdentausta et al. 2018). Kajian oleh Durcharme et al. (2000) juga mendapati penghapusan gen MMP-9 yang didasarkan dapat dikaitkan dengan pengurangan kejadian LV pecah. Perkaitan ini menekankan potensi MMP-9 sebagai penanda biologi untuk meramalkan pengubahsuaian jantung dan membimbing strategi terapeutik dalam rawatan ACS.

Perencatan ekspresi dan aktiviti MMP boleh mengurangkan risiko keparahan aterosklerosis dan terjadinya ACS. Perencat tisu metalloproteinase (TIMP) adalah protein endogen yang berfungsi untuk menentang aktiviti penguraian oleh MMP. Protein ini memainkan peranan penting dalam mengekalkan keseimbangan antara sintesis dan degradasi ECM (Hey & Linder 2024). TIMP akan mengikat pada tapak aktif ECM dan menghalang aktiviti enzimatik MMP, seterusnya melindungi komponen ECM daripada degradasi berlebihan (Chintalgattu et al. 2018). Proses ini dapat mengurangkan kepecahan plak aterosklerotik dan menurunkan risiko ACS. Di antara empat keluarga TIMP yang lain, TIMP 3 adalah yang paling unik kerana ia mempunyai afiniti yang tinggi terhadap proteoglikan dalam ECM dan mempunyai julat substrat yang luas, termasuk semua MMP (Takawale et al. 2015). Kajian rawak mendelian (MR) oleh Chen et al. (2022) mendapati kandungan TIMP 3 yang tinggi dalam serum boleh mengurangkan risiko ACS dalam kalangan pesakit kardiovaskular, manakala kandungan TIMP 3 yang rendah dikaitkan dengan peningkatan aktiviti proteolitik MMP (Fan & Kassiri 2020). Tambahan pula, kajian oleh Takawale et al. (2017) melaporkan TIMP 3 diekspresi dengan lebih rendah didalam tisu jantung dan darah pesakit kardiomiopati iskemik.

Kajian-kajian terdahulu telah mencadangkan mekanisme daripada beberapa laluan isyarat yang mungkin menjadi asas kepada kesan merokok terhadap peningkatan MMP dalam kalangan pesakit ACS. Antaranya ialah laluan isyarat melibatkan reseptor nikotinik asetilkolina alfa-1 ($\alpha 1nAChR$) dan kinase terkawal isyarat ekstraselular 1 dan 2 (ERK 1/2). Kajian oleh Ren et al. (2019) menunjukkan peranan nikotin dalam meningkatkan ekspresi MMP-2 dan MMP-9 dalam sel otot licin vascular tikus (MOVAS) dan makrofaj (RAW264.7) melalui laluan isyarat $\alpha 1nAChR$ dan calpain-1. Manakala, kajian oleh Liu et al. (2017) pula menunjukkan nikotin dengan penglibatan $\alpha 7nAChR$ merangsang fosforilasi kinase yang dikawal oleh isyarat

ERK 1/2 dan Ap-1 untuk meningkatkan pengeluaran MMP-2 dan MMP-9 dalam makrofaj (RAW264.7). Namun, kedua-dua kajian ini menggunakan garis sel haiwan sebagai sumber MMP. Mengkaji MMP menggunakan tisu plak dan sampel darah manusia memberikan penilaian secara langsung berkaitan biologi manusia. Sampel darah meliputi sel mononuklear darah periferi (PBMC) dan serum memberikan pandangan sistemik terhadap mekanisme penyakit. Kajian oleh Jönsson et al. (2011) mendapati ekspresi gen mRNA MMP-9 adalah tinggi dalam PBMC dan plasma pesakit. Walau bagaimanapun, mekanisme tepat bagaimana ini berlaku, khususnya melalui laluan isyarat yang terlibat, masih belum difahami sepenuhnya. Mengkaji laluan isyarat yang memodulasi ekspresi MMP dalam PBMC boleh meningkatkan pemahaman kita tentang peranan mereka dalam patogenesis ACS dan berpotensi membawa kepada strategi terapeutik baru.

Kesimpulannya, penyelidikan ini bertujuan untuk mengupas peranan laluan isyarat $\alpha 1nAChR$ -ERK dalam pembentukan MMP didalam sampel tisu plak aterosklerotik dan PBMC, demi memahami dengan lebih mendalam bagaimana merokok mencetuskan ketidakstabilan plak aterosklerotik dan meningkatkan risiko ACS. Rentetan itu, penyelidikan ini turut mengkaji hubungan antara MMP yang terhasil dengan keterukan penyakit dan kerosakan fungsi jantung. Dengan pemahaman ini, kita dapat mencadangkan mekanisme penyakit CAD ke arah langkah pencegahan dan rawatan yang lebih berkesan, serta memberikan peluang kepada orang ramai ke arah hidup yang lebih sihat.

1.2 PERMASALAHAN KAJIAN

Prevalens CAD didapati semakin meningkat dalam kalangan perokok lelaki, dengan ACS menjadi manifestasi klinikal yang utama. ACS lazimnya berpunca daripada kepecahan plak aterosklerotik yang tidak stabil, iaitu satu proses yang berkait rapat dengan peningkatan ekspresi MMP, terutamanya MMP-2 dan MMP-9. Enzim-enzim bersifat proteolitik ini menyumbang kepada penguraian matriks ekstraselular (ECM) dan dengan itu menjejaskan kestabilan plak aterosklerotik di dalam koronari arteri.

Kajian *in vitro* telah menunjukkan bahawa nikotin merangsang pelepasan MMP-2 dan MMP-9 melalui interaksinya dengan reseptor $\alpha 1nAChR$, seterusnya mengaktifkan laluan isyarat kinase yang dikawal selia oleh isyarat ERK 1/2. Namun begitu, penglibatan dan peranan laluan isyarat ini dalam meningkatkan ekspresi MMP-2 dan MMP-9 menggunakan sampel biologi manusia seperti tisu plak aterosklerotik, sel mononuklear darah periferi (PBMC) dan serum masih belum difahami sepenuhnya. Menjelaskan laluan isyarat ini adalah penting untuk memahami mekanisme molekul yang menghubungkan tabiat merokok dengan ketidakstabilan plak aterosklerotik dan perkembangan ACS.

Sehubungan itu, kajian ini turut meneliti bagaimana perubahan paras MMP berkait dengan tahap keterukan penyakit serta kemerosotan fungsi jantung. Pemahaman yang lebih mendalam mengenai hubungan ini dapat membantu menerangkan mekanisme asas patogenesis CAD, sekali gus menyokong pembangunan strategi pencegahan dan rawatan yang lebih berkesan.

1.3 PERSOALAN KAJIAN

Apakah peranan laluan isyarat $\alpha 1nAChR$ -ERK dalam pembentukan MMP dalam plak aterosklerotik koronari dan PBMC dalam kalangan perokok lelaki dengan ACS?

1.4 OBJEKTIF KAJIAN

1.4.1 Objektif Umum

Mengkaji peranan laluan isyarat $\alpha 1nAChR$ -ERK dalam pembentukan MMP dalam plak aterosklerotik koronari dan PBMC dalam kalangan perokok lelaki dengan ACS.


1.4.2 Objektif Khusus

- i. Mengukur ekspresi gen $\alpha 1nAChR$, ERK 1 dan 2, dan c-FOS dalam tisu plak aterosklerotik koronari dan PBMC daripada lelaki perokok dan bukan perokok dengan ACS.
- ii. Mengukur paras protein MMP-2, MMP-9, dan TIMP 3 dalam plak aterosklerotik koronari dan serum daripada lelaki perokok dan bukan perokok dengan ACS.
- iii. Mengkaji perkaitan hubungan antara MMP-2, MMP-9 dan TIMP 3 dengan tahap keterukan plak aterosklerotik (skor gensini) dalam kalangan lelaki perokok dan bukan perokok dengan CAD.
- iv. Mengkaji perkaitan hubungan antara MMP-2, MMP-9 dan TIMP 3 dengan parameter ekokardiografi (LVEF, E, E/A, $Av E/e'$ dan EDT) dalam kalangan lelaki perokok dan bukan perokok dengan CAD.

1.5 HIPOTESIS KAJIAN

- i. Ekspresi gen $\alpha 1nAChR$, ERK 1/2, c-FOS dan paras protein MMP-2, MMP-9 dan TIMP 3 dalam tisu plak aterosklerotik koronari adalah lebih tinggi pada lelaki perokok dengan ACS berbanding lelaki bukan perokok dengan ACS.
- ii. Ekspresi gen $\alpha 1nAChR$, ERK 1/2, c-FOS dalam PBMC dan paras protein MMP-2, MMP-9 dan TIMP 3 dalam serum adalah lebih tinggi pada lelaki perokok dengan ACS berbanding lelaki bukan perokok dengan ACS.
- iii. Terdapat hubungkait di antara MMP-2, MMP-9 dan TIMP 3 dengan tahap keterukan plak aterosklerotik (skor gensini) dalam kalangan lelaki perokok dan bukan perokok dengan CAD.

- iv. Terdapat hubungkait di antara MMP-2, MMP-9 dan TIMP 3 dengan parameter ekokardiografi (LVEF, E, E/A, Av E/e' dan EDT) dalam kalangan lelaki perokok dan bukan perokok dengan CAD.



RUJUKAN

- Abdullah, M.H.N., Othman, Z., Noor, H.M., Arshad, S.S., Yusof, A.K.M., Jamal, R., & Abdul Rahman, A.R. 2012. Peripheral blood gene expression profile of atherosclerotic coronary artery disease in patients of different ethnicity in Malaysia. *Journal of Cardiology* 60: 192–203. doi: 10.1016/j.jjcc.2012.05.009
- Acharya, S., Kundu, D. & Kim, K.M. 2021. β -arrestin1 and GPCR kinase 2 play permissive roles in Src-mediated endocytosis of $\alpha 4\beta 2$ nicotinic ACh receptors. *British Journal of Pharmacology* 178(17): 3498–3516.
- Addissouky, T. A., El Tantawy El Sayed, I., Ali, M. M. A., Wang, Y., El Baz, A., Elarabany, N., & Khalil, A. A. 2024. Oxidative stress and inflammation: Elucidating mechanisms of smoking-attributable pathology for therapeutic targeting. *Bulletin of the National Research Centre* 48(16). doi: 10.1186/s42269-024-01174-6
- Agrawal, V., Hardas, S., Gujar, H., & Phalgune, D. S. 2022. Correlation of serum ST2 levels with severity of diastolic dysfunction on echocardiography and findings on cardiac MRI in patients with heart failure with preserved ejection fraction. *Indian Heart Journal* 74(3): 229–234. doi:10.1016/j.ihj.2022.03.001
- Agur, T., Wedel, J., Bose, S., Sahankumari, A. G. P., Goodman, D., Kong, S. W., Ghosh, C. C., & Briscoe, D. M. 2022. Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4⁺ T cells. *American Journal of Transplantation* 22(3): 947-954
- Ahmed, S. H., Clark, L. L., Pennington, W. R., Webb, C. S., Bonnema, D. D., Leonardi, A. H., McClure, C. D., Spinale, F. G., & Zile, M. R. 2006. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. *Circulation* 113(17): 2089–2096
- Ahmeti, A., Bytyçi, F. S., Bielecka-Dabrowa, A., Bytyçi, I., & Henein, M. Y. 2021. Prognostic value of left atrial volume index in acute coronary syndrome: A systematic review and meta-analysis. *Clinical Physiology and Functional Imaging* 41(2): 128–135. doi: 10.1111/cpf.12689.
- Aimo, A., Januzzi, J. L., Vergaro, G., Petersen, C., Pasanisi, E. M., Molinaro, S., Passino, C., & Emdin, M. 2018. Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. *International Journal of*

Cardiology 273: 136–140. doi: 10.1016/j.ijcard.2018.07.117

- Ain, Q. U., Dewi, T. I. & Kurniati, N. F. 2023. Plasma levels of interleukin-6 and -18 significantly increase in patients with acute coronary syndrome. *Oman Medical Journal* 38(4): e532. doi: 10.5001/omj.2023.94.
- Akbari, T., Kazemi Fard, T., Fadaei, R., Rostami, R., Moradi, N., Movahedi, M., & Fallah, S. 2023. Evaluation of MMP-9, IL-6, TNF- α levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease. *Journal of Cardiovascular and Thoracic Research* 15: 223–230.
- Aksu, F., & Ahmed, S. A. 2024. Gensini score's severity and its relationship with risk factors for coronary artery disease among patients who underwent angiography in Somalia's largest PCI centre. *International Journal of General Medicine* 17: 187–192. doi: 10.2147/IJGM.S384626
- Aksu, F., & Ahmed, S. A. 2024. Gensini score's severity and its relationship with risk factors for coronary artery disease among patients who underwent angiography in Somalia's largest PCI centre. *International Journal of General Medicine* 17: 187–192. doi: 10.2147/IJGM.S384626.
- Al-Roub, A., Akhter, N., Al-Rashed, F., Wilson, A., Alzaid, F., Al-Mulla, F., Sindhu, S., & Ahmad, R. 2023. TNF α induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1/JNK/ERK/NF- κ B signaling pathways. *Scientific Reports* 13: 14351.
- Alam, M., Samad, B. A., Wardell, J., Andersson, E., Höglund, C., & Nordlander, R. 2002. Acute effects of smoking on diastolic function in healthy participants: Studies by conventional Doppler echocardiography and Doppler tissue imaging. *Journal of the American Society of Echocardiography* 15(10): 1232–1237.
- Alam, M., Witt, N., Nordlander, R., & Samad, B. A. 2007. Detection of abnormal left ventricular function by Doppler tissue imaging in patients with a first myocardial infarction and showing normal function assessed by conventional echocardiography. *European Journal of Echocardiography* 8(1): 37–41. doi: 10.1016/j.euje.2005.12.012
- Alpert, J. S., Thygesen, K., Antman, E., Bassand, J. P. 2000. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Journal of the American College of Cardiology* 36(3): 959–69.

- Alshehri, A. M., Azoz, A. M., Shaheen, H. A., Farrag, Y. A., Khalifa, M. A., & Youssef, A. 2013. Acute effects of cigarette smoking on the cardiac diastolic functions. *Journal of the Saudi Heart Association* 25(3): 173–179. doi:10.1016/j.jsha.2013.03.003
- Ambrose, J. A., & Barua, R. S. 2004. The pathophysiology of cigarette smoking and cardiovascular disease: An update. *Journal of the American College of Cardiology* 43(10): 1731–1737. doi:10.1016/j.jacc.2003.12.047
- Ambrose, J.A., & Singh, M. 2015. Pathophysiology of coronary artery disease leading to acute coronary syndromes. *F1000Prime Reports*, 1–5.
- American Heart Association. 2024. *Acute coronary syndrome*. Diperoleh daripada <https://www.heart.org/en/health-topics/heart-attack/about-heart-attacks/acute-coronary-syndrome>
- American Heart Association. n.d. *Ejection fraction — Heart failure measurement*. Diperoleh daripada <https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement>
- Amin, M., Pushpakumar, S., Muradashvili, N., Kundu, S., Tyagi, S. C., & Sen, U. 2016. Regulation and involvement of matrix metalloproteinases in vascular diseases. *Frontiers in Bioscience (Landmark Edition)* 21: 89–118
- Aminuddin, A., Cheong, S.S., Roos, N.A.C., & Ugusman, A. 2023. Smoking and Unstable Plaque in Acute Coronary Syndrome: A Systematic Review of The Role of Matrix Metalloproteinases. *International Journal of Medical Sciences* 20 (4): 482-492. doi: 10.7150/ijms.79889
- Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., Levine, G. N., Liebson, P. R., Mukherjee, D., Peterson, E. D., Sabatine, M. S., Smalling, R. W., & Zieman, S. J. 2014. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. *Circulation* 130(25). doi: 10.1161/CIR.0000000000000134
- Andersson, L., Zhang, Y., Gomez, M. F., Vergara, R., Holm, A., & Borjesson, M. 2015. Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia. *Cardiovascular Research* 107(4): 478–486. doi:10.1093/cvr/cvv186
- Anzai, T. 2013. Post-infarction inflammation and left ventricular remodeling: A double-edged sword. *Circulation Journal* 77: 580–587
- Aparicio, L. S. Y., Fierro, Á. de J. L., Aranda Abreu, G. E., Toledo Cárdenas, R., García

- Hernández, L. I., Coria Ávila, G. A., Rojas Durán, F., Aguilar, M. E. H., Denes, J. M., Chi-Castañeda, L. D., & Pérez Estudillo, C. A. 2022. Current opinion on the use of c-Fos in neuroscience. *Neurology Science* 3(4): 687–702. doi: 10.3390/neurosci3040050
- Arpino, V., Brock, M., & Gill, S. E. 2015. The role of TIMPs in regulation of extracellular matrix proteolysis. *Matrix Biology* 44: 247–254. doi: 10.1016/j.matbio.2015.03.005
- Ashley, E. A., & Niebauer, J. 2004. *Understanding the echocardiogram*. In Cardiology Explained (Chapter 4). Remedica, London. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK2215/>
- Aslan, R., Akhan, O., Ardahani, I., & Akyuz, O. 2022. Relationship between coronary artery tortuosity and left ventricular diastolic functions. *Lokman Hekim Health Sciences* 2(1): 14–19. doi:10.14744/lhhs.2022.12001
- Augé, N., Maupas-Schwalm, F., Elbaz, M., Thiers, J.-C., Waysbort, A., Itohara, S., Hirsch, E., Castier, Y., Legrand, M., & Nègre-Salvayre, A. 2004. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. *Circulation* 110(5): 571–578. doi: 10.1161/01.CIR.0000136995.83451.1D
- Bachmann, J. M., Willis, B. L., Ayers, C. R., Khera, A., & Berry, J. D. 2012. Association between family history and coronary heart disease death across long-term follow-up in men: The Cooper Center Longitudinal Study. *Circulation* 125(25): 3092–3098
- Baghirova, S., Hughes, B. G., Poirier, M., Kondo, M. Y., & Schulz, R. 2016. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. *Journal of Molecular and Cellular Cardiology* 94: 153–161.
- Baigent, C., Blackwell, L., Emberson, J., Holland, L. E., Reith, C., Bhala, N., Peto, R., Barnes, E. H., Keech, A., Simes, J., & Collins, R. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. *The Lancet* 376: 1670–1681.
- Bajraktari, G., Miccoli, M., Buralli, S., Fontanive, P., Elezi, S., Metelli, M. R., Baggiani, A., & Dini, F. L. 2012. Plasma metalloproteinase-9 and restrictive filling pattern as major predictors of outcome in patients with ischemic cardiomyopathy. *European Journal of Internal Medicine* 23(7): 616–620. doi: 10.1016/j.ejim.2012.04.013
- Balla, C., Pavasini, R., & Ferrari, R. 2018. Treatment of Angina: Where Are

We? *Cardiology* 140(1):52-67

Banks, E., Joshy, G., Korda, R.J., Stavreski, B., Soga, K., Egger, S., Day, C., Clarke, N.E., Lewington, S., & Lopez, A.D. 2019. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. *BMC Medicine* 17(1):128. doi: 10.1186/s12916-019-1351-4

Barakat, A., & Alsaadi, A. R. 2022. An echocardiographic algorithm for predicting coronary artery disease: is it time to establish one?. *European Heart Journal* 43(1): ehab849.071. doi: 10.1093/eurheartj/ehab849.071

Basit, H., Malik, A., & Huecker, M. R. 2023. Non–ST-Segment Elevation Myocardial Infarction. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK513228/>

Bekkering, S., Joosten, L. A., van der Meer, J. W., Netea, M. G., & Riksen, N. P. 2013. Trained innate immunity and atherosclerosis. *Curr Opin Lipidol* 24(6):487-92. doi: 10.1097/MOL.0000000000000023

Ben Braiek, A., Chahed, H., Dumont, F., Abdelhak, F., Hichem, D., Gamra, H., & Baudin, B. 2021. Identification of biomarker panels as predictors of severity in coronary artery disease. *Journal of Cellular and Molecular Medicine* 25: 1518–1530.

Bergmark, B.A., Mathenge, N., Merlini, P.A., Lawrence-Wright, M.B., & Giugliano, R.P. 2022. Acute coronary syndromes. *The Lancet* 399: 1347–1358. doi: 10.1016/S0140-6736(21)02391-6

Bhupal, V. S. R., & Sampath, K. 2024. Prognostic significance of left atrial volume index in patients with acute coronary syndrome. *Journal of the Practice of Cardiovascular Sciences* 10(2): 82–87. doi: 10.4103/jpcs.jpcs_37_24

Biering-Sørensen, T., Jensen, J. S., Pedersen, S., Galatius, S., Hoffmann, S., Jensen, M. T., & Mogelvang, R. 2014. Doppler tissue imaging is an independent predictor of outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *Journal of the American Society of Echocardiography* 27(3): 258–267. doi: 10.1016/j.echo.2013.11.005

Biering-Sørensen, T., Jensen, J. S., Pedersen, S., Galatius, S., Hoffmann, S., Jensen, M. T., Bech, J., Fritz-Hansen, T., & Mogelvang, R. 2014. Doppler tissue imaging is an independent predictor of outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *Journal of the American Society of Echocardiography* 27(3): 258–67.

- Binzamil, J. M., Albogmi, L. J., Alburaih, T. A., ALotaibi, M. J., AlHazmi, T. A., Awaidha Al-Rubai, A. K., Barnawi, A., Alhashah, S. Y., Hilal Al-Harhi, F. H., & Al-Otaibi, S. A. 2025. A Comparative Study of Cardiac Biomarkers (Troponin I, CK-MB, and BNP) in Early Diagnosis of Acute Coronary Syndrome. *Vascular and Endovascular Review* 8(8s): 372-377. doi: 10.64149Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F., Tiret, L., & The AtheroGene Investigators. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase-9 and prognosis of patients with cardiovascular disease. *Circulation* 107: 1579–1585
- Bonnema, D. D., Webb, C. S., Pennington, W. R., Stroud, R. E., Leonardi, A. E., Clark, L. L., McClure, C. D., Finklea, L., & Spinale, F. G. 2007. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). *Journal of Cardiac Failure* 13(7): 530–540.
- Bouzidi, N., & Gamra, H. 2023. Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention. *BMC Cardiovascular Disorders* 23: 586. doi:
- Brown, B. A., Williams, H., & George, S. J. 2017. Evidence for the involvement of matrix-degrading metalloproteinases (MMPs) in atherosclerosis. *Progress in Molecular Biology and Translational Science* 147: 197–237. doi: 10.1016/bs.pmbts.2017.01.004
- Brown, J. C., Gerhardt, T. E., & Kwon, E. 2023. *Risk factors for coronary artery disease*. StatPearls Publishing. Dipheroleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK554410/>
- Brunner, S., Kim, J.-O., & Methe, H. 2010. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. *American Journal of Cardiology* 105(4): 429–434. doi: 10.1016/j.amjcard.2009.10.013
- Bräuninger, H., Krüger, S., Bacmeister, L., Nyström, A., Eyerich, K., Westermann, D., & Lindner, D. 2023. Matrix metalloproteinases in coronary artery disease and myocardial infarction. *Basic Research in Cardiology* 118(1): 18. doi:10.1007/s00395-023-00987-2
- Buckley, L. F., Agha, A. M., Claggett, B. L., Yu, B., Hussain, A., Nambi, V., Chen, L. Y., Matsushita, K., Hoogeveen, R. C., Ballantyne, C. M., & Shah, A. M. 2023. MMP-2 associates with incident heart failure and atrial fibrillation: The ARIC study. *Circulation: Heart Failure* 16(11). doi:10.1161/CIRCHEARTFAILURE.123.010849

- Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. 2020. The roles of matrix metalloproteinases and their inhibitors in human diseases. *International Journal of Molecular Sciences* 21(24): 9739.
- Cargnello, M., & Roux, P. P. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiology and Molecular Biology Reviews* 75(1): 50-83. doi: 10.1128/MMBR.00031-10.
- Casagrande, V., Menghini, R., Menini, S., Marino, A., Marchetti, V., Cavallera, M., Fabrizi, M., Hribal, M. L., Pugliese, G., Gentileschi, P., Schillaci, O., Porzio, O., Lauro, D., Sbraccia, P., Lauro, R., & Federici, M. 2011. Overexpression of tissue inhibitor of metalloproteinase-3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. *Arteriosclerosis, Thrombosis, and Vascular Biology* 32(1): 74–81.
- Çelik, Ö., Şahin, A. A., Sarıkaya, S., & Uygur, B. 2020. Correlation between serum matrix metalloproteinase and myocardial fibrosis in heart failure patients with reduced ejection fraction: A retrospective analysis. *Anatolian Journal of Cardiology* 24(4): 303–308. doi:10.14744/AnatolJCardiol.2020.54937
- Centner, A. M., Bhide, P. G., & Salazar, G. 2020. Nicotine in Senescence and Atherosclerosis. *Cells* 9(4): 1035. doi: 10.3390/cells9041035
- Cerisano, G., Bolognese, L., Buonamici, P., Valenti, R., Migliorini, A., Santoro, G. M., Carrabba, N., Antonucci, D., Moschi, G., & Antonucci, D. 2001. Prognostic implications of restrictive left ventricular filling in reperfused anterior acute myocardial infarction. *Journal of the American College of Cardiology* 37(3): 793–799.
- Cesare, M. D., Bixby, H., Gaziano, T., Hadeed, L., Kabudula, C., McGhie, D. V., Mwangi, J., Pervan, B., Perel, P., Piñeiro, D., Taylor, S., & Pinto, F. 2023. *World Heart Report 2023: Confronting the world's number one killer*. Geneva, Switzerland: World Heart Federation.
- Cesare, M. D., Perel, P., Taylor, S., Kabudula, C., Bixby, H., Gaziano, T. A., McGhie, D. V., Mwangi, J., Pervan, B., Narula, J., Pineiro, D., Pinto, F. J. 2024. The Heart of the World. *Glob Heart* 19(1): 11. doi: 10.5334/gh.1288
- Chandrasekar, B., Mummidi, S., Mahimainathan, L., Patel, D. N., Bailey, S. R., Imam, S. Z., Greene, W. C., & Valente, A. J. 2006. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-κB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by

- atorvastatin. *Journal of Biological Chemistry* 281(22): 15099–15109. doi: 10.1074/jbc.M600200200
- Charach, L., Blatt, A., Jonas, M., Teodorovitz, N., Haberman, D., Gendelman, G., Grosskopf, I., & George, J. 2021. Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. *Medicine* 100(41): e27331. doi: 10.1097/MD.00000000000027331
- Chen, F., Eriksson, P., Hansson, G., Herzfeld, I., Klein, M., Hansson, L.-O., & Valen, G. 2005. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. *International Journal of Molecular Medicine* 15(1): 57–65. doi:10.3892/ijmm.15.1.57
- Chen, H., Chen, S., Ye, H., & Guo, X. 2022. Protective effects of circulating TIMP3 on coronary artery disease and myocardial infarction: A Mendelian randomization study. *Journal of Cardiovascular Development and Disease* 9(8): 277. doi: 10.3390/jcdd9080277.
- Chen, X., Liu, F., Xu, H., Zha, D., Xiu, J., Guo, J., & Zhang, A. 2017. Left ventricular diastolic dysfunction in patients with ST-elevation myocardial infarction following early and late reperfusion by coronary intervention. *International Journal of Cardiology* 228: 886–889.
- Chen, Y., Fan, Y., Han, C., Yan, Z., Cai, X., & Jun, Y. 2005. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. *Cardiovascular Research*, 67(3): 656–664. doi: 10.1016/j.cardiores.2005.05.007
- Chen, Y., Waqar, A. B., Nishijima, K., Ning, B., Kitajima, S., Matsuhisa, F., Chen, L., Liu, E., Koike, T., Yu, Y., Zhang, J., Chen, Y. E., Sun, H., Liang, J., & Fan, J. 2020. Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. *Journal of Cellular and Molecular Medicine* 24: 4261–4274.
- Chen, Z. W., Yang, H. B., Chen, Y. H., Lin, Y. J., Li, J. L., & Wu, M. J. 2017. Impact of multi-vessel therapy on the risk of periprocedural myocardial injury after elective coronary intervention: Exploratory study. *BMC Cardiovascular Disorders* 17: 69.
- Chetrit, M., Cremer, P., & Klein, A. 2020. Imaging of diastolic dysfunction in community-based epidemiological studies and randomized controlled trials of HFpEF. *JACC: Cardiovascular Imaging* 13(1_Part_2): 310–326. doi: 10.1016/j.jcmg.2019.10.022

- Chew, D. S., Wilton, S. B., Kavanagh, K., Southern, D. A., Tan-Mesiatowsky, L. E., & Exner, D. V. 2018. Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling. *American Heart Journal* 198: 91–96. doi: 10.1016/j.ahj.2017.11.014
- Chiao, Y. A., Ramirez, T. A., Zamilpa, R., Okoronkwo, S. M., Dai, Q., Zhang, J., Jin, Y. F., & Lindsey, M. L. 2012. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. *Cardiovascular Research* 96(3): 444–455. doi:10.1093/cvr/cvs275
- Chintalgattu, V., Greenberg, J., Singh, S., Chiueh, V., Gilbert, A., O'Neill, J. W., Smith, S., Jackson, S., Khakoo, A. Y., Lee, T. W. 2018. Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model. *Cardiometabolic Disorders & Therapeutic Discovery* doi: 10.1002/prp2.442
- Cho, J. H., Shin, S. Y., Kim, H., Kim, M., Byeon, K., Jung, M., Kang, K. W., Lee, W. S., Kim, S. W., & Lip, G. Y. H. 2024. Smoking cessation and incident cardiovascular disease. *JAMA Network Open* 7(11): e2442639. doi: 10.1001/jamanetworkopen.2024.42639
- Chrestia, J. F., Turani, O., Rodriguez Araujo, N., Hernando, G., Esandi, M. C. & Bouzat, C. 2023. Regulation of nicotinic acetylcholine receptors by post-translational modifications. *Pharmacological Research* 190: 106712
- Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. 2016. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 316(19). doi:10.1001/jama.2015.15629
- Christia, P., & Frangogiannis, N. G. 2013. Targeting inflammatory pathways in myocardial infarction. *European Journal of Clinical Investigation* 43: 986–995.
- Chu, J. W., Jones, G. T., Tarr, G. P., Phillips, L. V., Wilkins, G. T., van Rij, A. M., & Williams, M. J. 2011. Plasma active matrix metalloproteinase-9 associated with diastolic dysfunction in patients with coronary artery disease. *International Journal of Cardiology* 147(2): 336–338. doi:10.1016/j.ijcard.2010.12.093
- Chu, J. W., Jones, G. T., Tarr, G. P., Phillips, L. V., Wilkins, G. T., van Rij, A. M., & Williams, M. J. A. 2013. Plasma active matrix metalloproteinase-9 and indices of diastolic function in patients with preserved systolic function. *International Journal of Cardiology* 167(4): 1242–1246. doi:10.1016/j.ijcard.2012.03.031

- Collet, J.P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., Gale, C. P., Gilard, M., Jobs, A., Jüni, P., Lambrinou, E., Lewis, B. S., Mehilli, J., Meliga, E., Merkely, B., Mueller, C., Roffi, M., Rutten, F. H., Sibbing, D., & Siontis, G. C. M. 2021. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal* 42(14): 1289–1367.
- Cortez, D. M., Feldman, M. D., Mummidi, S., Valente, A. J., Steffensen, B., Vincenti, M., Barnes, J. L., & Chandrasekar, B. 2007. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP- β , NF- κ B, and AP-1 activation. *American Journal of Physiology – Heart and Circulatory Physiology* 293(6): H3356–H3365. doi: 10.1152/ajpheart.00928.2007
- Critchley, J. A., & Capewell, S. (2003). Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. *JAMA* 290: 86–97.
- Cruz, F., Jauregui, F., Aguilar, A., García, J., & Luquin, S. 2022. Immediate early gene c-Fos in the brain: Focus on glial cells. *Brain Sciences* 12: 687.
- Cui, N., Hu, M., & Khalil, R. A. 2017. Biochemical and biological attributes of matrix metalloproteinases. *Progress in Molecular Biology and Translational Science* 147: 1–73. doi: 10.1016/bs.pmbts.2017.02.005
- Dabek, J., Glogowska-Ligus, J., & Szadorska, B. 2013. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients. *Journal of Postgraduate Medicine* 59: 115–120.
- Deanfield, J.E., Halcox, J.P., & Rabelink, T.J. 2007. Endothelial function and dysfunction: testing and clinical relevance. *Circulation* 115(10): 1285-95. doi:10.1161/CIRCULATIONAHA.106.652859.
- Del Buono, M. G., Moroni, F., Montone, R. A., Azzalini, L., Sanna, T., & Abbate, A. 2022. Ischemic cardiomyopathy and heart failure after acute myocardial infarction. *Current Cardiology Reports* 24(10): 1505-1515. doi: 10.1007/s11886-022-01766-6
- DeLeon-Pennell, K. Y., Meschiari, C. A., Jung, M., & Lindsey, M. L. 2017. Matrix metalloproteinases in myocardial infarction and heart failure. *Progress in Molecular Biology and Translational Science* 147: 75-100. doi: 10.1016/bs.pmbts.2017.02.001

- Delrue, C., & Speeckaert, M. M. 2024. Tissue inhibitor of metalloproteinases-2 (TIMP-2) as a prognostic biomarker in acute kidney injury: A narrative review. *Diagnostics* 14(13): 1350. doi: 10.3390/diagnostics14131350.
- Diabasana, Z., Perotin, J.M., Belgacemi, R., Ancel, J., Mulette, P., Delepine, G., Gosset, P., Maskos, U., Polette, M., Deslée, G. & Dormoy, V. 2020. Nicotinic receptor subunits atlas in the adult human lung. *International Journal of Molecular Sciences* 21(20): 7446.
- Duan, F., Zeng, C., Liu, S., Gong, J., Hu, J., Li, H., & Tan, H. 2021. α 1-nAChR-Mediated Signaling Through Lipid Raft is Required for Nicotine-Induced NLRP3 Inflammasome Activation and Nicotine-Accelerated Atherosclerosis. *Frontiers in Cell Development Biology* doi: 10.3389/fcell.2021.724699
- Dobaczewski, M., Bujak, M., Zymek, P., Ren, G., Entman, M. L., & Frangogiannis, N. G. 2006. Extracellular matrix remodeling in canine and mouse myocardial infarcts. *Cell and Tissue Research* 324(3): 475–488. doi:10.1007/s00441-005-0144-6
- Doll, R., Peto, R., Boreham, J., & Sutherland, I. 2004. Mortality in relation to smoking: 50 years' observations on male British doctors. *British Medical Journal* 328: 1519.
- Ducharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E., Schoen, F. J., Kelly, R. A., Werb, Z., Libby, P., & Lee, R. T. 2000. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. *The Journal of Clinical Investigation* 106(1): 55–62. doi: 10.1172/JCI8768
- Dunbar, S.B., Khavjou, O.A., Bakas, T., Hunt, G., Kirch, R.A., Leib, A.R., Morrison, R.S., Poehler, D.C., Roger, V.L., Whitsel, L.P. 2018. Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association. *Circulation* 137(19): e558-e577.
- Dyrbuś, K., Gąsior, M., Desperak, P., Osadnik, T., Nowak, J., & Banach, M. 2019. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. *Atherosclerosis* 288: 33–41. doi:
- Dziewierz, A., Siudak, Z., Rakowski, T., Zasada, W., Dubiel, J. S., & Dudek, D. 2010. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). *American Journal of Cardiology* 106(3): 342–

347. doi: 10.1016/j.amjcard.2010.03.029

Ehud, S., Yehuda, A., Keren, A., Alik, S., Solomon, B., Hanoch, H., & Micha, F. S. 2003. Prognostic value of global myocardial performance indices in acute myocardial infarction: Comparison to measures of systolic and diastolic left ventricular function. *Cardiology* 124(5): 1645–1651.

El-Barbary, A., Elsayed, M. A., Selim, Y. A. Y., Elkaffas, S. M. H., Sabit, H., Arneth, B., Taghiyev, Z. T., & Tantawy, M. A. 2025. Correlation between coronary artery disease severity detected by CT coronary angiography and grade of left ventricular diastolic dysfunction detected by echocardiography. *Journal of Clinical Medicine* 14(20): 7218.

Elabscience. n.d. BCA protein colorimetric assay kit. Diperoleh daripada <https://www.elabscience.com>

Elabscience. n.d. Human MMP and TIMP ELISA Kit: Instruction Manual (Catalog No. E-EL-H1445, E-EL-H6075, E-EL-H1454). Elabscience Biotechnology Inc. Diperoleh daripada <https://www.elabscience.com>

Esmailzadeh, M., Parsaei, M., & Maleki, M. 2013. The Role of Echocardiography in Coronary Artery Disease and Myocardial Infarction. *Journal of Tehran University Heart Center* 8 (1): 1-13

Ezhov, M., Safarova, M., Afanasieva, O., Mitroshkin, M., Matchin, Y., & Pokrovsky, S. 2019. Matrix metalloproteinase-9 as a predictor of coronary atherosclerotic plaque instability in stable coronary heart disease patients with elevated lipoprotein(a) levels. *Biomolecules* 9(4): 129. doi: 10.3390/biom9040129.

Falcinelli, E., De Paolis, M., Boschetti, E., & Gresele, P. 2022. Release of MMP-2 in the circulation of patients with acute coronary syndromes undergoing percutaneous coronary intervention: Role of platelets. *Thrombosis Research* 216: 84-89

Falk, E., Nakano, M., Benton, J. F., Finn, A. V., & Virmani, R. 2013. Update on acute coronary syndromes: The pathologists' view. *European Heart Journal*, 34(10): 719–728. doi: 10.1093/eurheartj/ehs411.

Fan, D., & Kassiri, Z. 2020. Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Therapeutic Implications in Cardiovascular Pathology. *Frontiers in Physiology* 11: 661, doi: 10.3389/fphys.2020.00661

Fan, D., Takawale, A., Lee, J., & Kassiri, Z. 2012. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. *Fibrogenesis & Tissue Repair* 5(1): 15. doi: 10.1186/1755-1536-5-15

- Faro, D., Laudani, C., Agnello, F., Gammeri, S., Buccheri, S., Cavallaro, C., et al. 2023. Complete percutaneous coronary revascularization in acute coronary syndromes with multivessel coronary disease: a systematic review. *JACC: Cardiovascular Interventions* 16(19): 2347–2364.
- Fichtlscherer, S., Breuer, S., Schächinger, V., Dimmeler, S. & Zeiher, A.M. 2004. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. *European Heart Journal* 25(16): 1412–1418.
- Flor, L. S., Anderson, J. A., Ahmad, N., Aravkin, A., Carr, S., Dai, X., Gil, G. F., Hay, S. I., Malloy, M. J., McLaughlin, S. A., Mullany, E. C., Murray, C. J. L., O'Connell, E. M., Okereke, C., Sorensen, R. J. D., Whisnant, J., Zheng, P., & Gakidou, E. 2024. Health effects associated with exposure to secondhand smoke: a Burden of Proof study. *Nature Medicine* 30: 149–167. doi: 10.1038/s41591-023-02743-4
- Fomovsky, G. M., Thomopoulos, S., & Holmes, J. W. 2010. Contribution of extracellular matrix to the mechanical properties of the heart. *Journal of Molecular and Cellular Cardiology* 48(3): 490-6. doi: 10.1016/j.yjmcc.2009.08.003.
- Fonseca, G. J., Tao, J., Westin, E. M., Duttke, S. H., Spann, N. J., Strid, T., Shen, Z., Stender, J.D., Sakai, M., Link, V. M., Benner, C., & Glass, C. K. 2019. Diverse motif ensembles specify non-redundant DNA binding activities of AP-1 family members in macrophages. *Nature Communication*, 10: 414. doi:10.1038/s41467-018-08236-0
- Frangogiannis, N. G. 2017. The extracellular matrix in myocardial injury, repair, and remodeling. *Journal of Clinical Investigation* 127(5): 1600-1612. doi: 10.1172/JCI87491.
- Fu, X., Zong, T., Yang, P., Li, L., Wang, S., Wang, Z., Li, M., Li, X., Zou, Y., Zhang, Y., Aung, L. H.H., Yang, Y., & Y, T. 2021. Nicotine: Regulatory roles and mechanisms in atherosclerosis progression. *Food and Chemical Toxicology* 151: 112154. doi: 10.1016/j.fct.2021.112154
- Fukuda, D., Shimada, K., Tanaka, A., Kusuyama, T., Yamashita, H., Ehara, S., Nakamura, Y., Kawarabayashi, T., Iida, H., Yoshiyama, M., & Yoshikawa, J. 2006. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. *American Journal of Cardiology* 97(2): 175–180. doi: 10.1016/j.amjcard.2005.08.020
- Funayama, H., Yoshioka, T., Ishikawa, S., Momomura, S., & Kario, K. 2021. Close

- Association of Matrix Metalloproteinase-9 Levels With the Presence of Thin-Cap Fibroatheroma in Acute Coronary Syndrome Patients: Assessment by Optical Coherence Tomography and Intravascular Ultrasonography. *Cardiovascular Revascularization Medicine* 32: 5–10. doi: 10.1016/j.carrev.2020.12.033
- Furtado, R. H. M., Juliasz, M. G., Chiu, F. Y. J., Bastos, L. B. C., Dalcoquio, T. F., Lima, F. G., Rosa, R., Caporrino, C. A., Bertolin, A., Genestreti, P. R. R., Ribeiro, A. S., Andrade, M. C., Giraldez, R. R. C. V., Baracioli, L. M., Zelniker, T. A., & Nicolau, J. C. 2023. Long-term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction. *ESC Heart Failure* 10(1): 442–452. doi:
- Gallucci, G., Tartarone, A., Lerosé, R., Lalinga, A.V., & Capobianco, A.M. 2020. Cardiovascular risk of smoking and benefits of smoking cessation. *Journal of Thoracic Disease* 12(7): 3866–3876. doi: 10.21037/jtd.2020.02.47.
- Gao, L., Zheng, Y. J., Gu, S. S., Tan, J. L., Paul, C., Wang, Y. G., & Yang, H. T. 2014. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion. *Journal of Molecular and Cellular Cardiology* 77: 102–112. doi: 10.1016/j.yjmcc.2014.10.004.
- GBD 2017 Risk Factor Collaborators. 2018. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* 392: 1923–1994.
- GeneCopoeia, Inc. 2024. All-in-One qPCR Primer user manual (Catalog No. HQP091806, HQP014848, HQP054675, HQP006940)
- Giannakos, E., Vardali, E., Bartekova, M., Fogarassyova, M., Barancik, M., & Radosinska, J. 2016. Changes in activities of circulating MMP-2 and MMP-9 in patients suffering from heart failure in relation to gender, hypertension and treatment: A cross-sectional study. *Physiology Research* 65(Suppl.1): S149–S152. doi: 10.33549/physiolres.933412
- Gillen, C., & Goyal, A. 2022. Stable Angina. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK559016/>
- Goh, R. S. J., Chong, B., Jayabaskaran, J., Jauhari, S. M., Chan, S. P., Kueh, M. T. W., Shankar, K., Li, H., Chin, Y. H., Kong, G., Anand, V. V., Chan, K. A., Sukmawati, I., Toh, S. A., Muthiah, M., Wang, J. W., Tse, G., Mehta, A., Fong,

- A., Baskaran, L., Zhong, L., Yap, J., Yeo, K. K., Hausenloy, D. J., Tan, J. W. C., Chao, T. F., Li, Y. H., Lim, S. L., Chan, K. H., Loh, P. H., Chai, P., Yeo, T. C., et al. 2024. The burden of cardiovascular disease in Asia from 2025 to 2050: A forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. *The Lancet Regional Health – Western Pacific* 49: 101138. doi: 10.1016/j.lanwpc.2024.101138
- Goto, T., Ohte, N., Wakami, K., Asada, K., Fukuta, H., Mukai, S., Tani, T., & Kimura, G. 2010. Usefulness of plasma brain natriuretic peptide measurement and tissue Doppler imaging in identifying isolated left ventricular diastolic dysfunction without heart failure. *The American Journal of Cardiology* 106(1): 87–91.
- Gresele, P., Falcinelli, E., Momi, S., Petito, E., & Sebastiano, M. 2021. Platelets and matrix metalloproteinases: A bidirectional interaction with multiple pathophysiologic implications. *Hämostaseologie* 41: 136–145.
- Gu, C., Wang, F., Zhao, Z., Wang, H., Cong, X., & Chen, X. 2017. Lysophosphatidic acid is associated with atherosclerotic plaque instability by regulating nf-kb dependent matrix metalloproteinase-9 expression via lpa(2) in macrophages. *Frontiers in Physiology* 8: 266. doi: 10.3389/fphys.2017.00266
- Guo, R., Li, Y., Sun, H., Wu, J., Liu, W., & Xu, Y. 2011. Evaluation of left ventricular diastolic function in patients presenting with acute coronary syndrome by Doppler tissue imaging. *International Journal of Cardiology* 152(Suppl. 1). doi:
- Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. 2020. ERK/MAPK signalling pathway and tumorigenesis (Review). *Experimental and Therapeutic Medicine* 19: 1997–2007. doi: 10.3892/etm.2020.8454
- Gupta, R., Gupta, S., Sharma, S., Sinha, D. N., & Mehrotra, R. 2019. Risk of coronary heart disease among smokeless tobacco users: Results of systematic review and meta-analysis of global data. *Nicotine & Tobacco Research* 21: 25–31.
- Gupta, S., & Booth, J. W. 2010. ERK phosphorylation and tumor necrosis factor-alpha production by monocytes are persistent in response to immobilized IgG. *Biochemical and Biophysical Research Communications* 402(2): 301–304. doi: 10.1016/j.bbrc.2010.10.020
- Güler, B., Korkmaz, A., Öztürk, C., Aydın, S., Yıldırım, A., & Şentürk, H. 2024. Differentiation of constrictive pericarditis and restrictive cardiomyopathy using multi-modality imaging methods. *Türk Kardiyol Dern Ars* 52(Suppl 1): S1–S206.
- Hahad, O., Schmitt, V. H., Kuntic, M., Daiber, A., & Münzel, T. 2023. Tobacco

- smoking and vascular biology and function: Evidence from epidemiological and experimental studies. *European Journal of Physiology* 475: 701–714. doi: 10.1007/s00424-023-02805-z
- Hajar, R. 2017. Risk factors for coronary artery disease: Historical perspectives. *Heart Views* 18(3): 109–114.
- Halliday, B. P., Senior, R., & Pennell, D. J. 2021. Assessing left ventricular systolic function: From ejection fraction to strain analysis. *European Heart Journal* 42: 789–797. doi: 10.1093/eurheartj/ehaa587
- Hamed, G. M., & Fattah, M. F. A. 2015. Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. *Clinical and Applied Thrombosis/Hemostasis* 21(8): 705–711. doi: 10.1177/1076029614567309
- Hamed, G. M., Tawfik, H. M., El-Maadawy, E. A., El-Aasar, A. S., & El Menshawy, N. 2015. Clinical relevance of matrix metalloproteinase-9 in patients with acute coronary syndrome. *Clinical and Applied Thrombosis/Hemostasis* 21(8), 705–711. doi: 10.1177/1076029614567309
- Hannan, M., Kringle, E., Hwang, C. L., & Laddu, D. 2021. Behavioral medicine for sedentary behavior, daily physical activity, and exercise to prevent cardiovascular disease: A review. *Current Atherosclerosis Reports* 23(9): 48.
- Hanson, M. A., Fareed, M. T., Argenio, S. L., Agunwamba, A. O., & Hanson, T. R. 2013. Coronary artery disease. Primary Care. *Clinics in Office Practice* 40(1): 1–16. Doi: 10.1016/j.pop.2012.12.001
- Hao, W. R., Cheng, C. H., Liu, J. C., Chen, H. Y., Chen, J. J., & Cheng, T. H. 2024. Understanding Galectin-3's role in diastolic dysfunction: A contemporary perspective. *Life (Basel)* 14(7): 906. doi:10.3390/life14070906
- Hassanin, A., Brener, S. J., Lansky, A. J., Xu, K., & Stone, G. W. 2015. Prognostic impact of multivessel versus culprit-vessel-only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. *EuroIntervention*. doi: 10.4244/EIJY14M08_05
- Henein, M. Y., & Lindqvist, P. 2015. Assessment of left ventricular diastolic function by Doppler echocardiography. *Cardiac Failure Review* 1(2): 87–89. doi: 10.15420/cfr.2015.1.2.87.
- Hey, S., & Linder, S. 2024. Matrix metalloproteinases at a glance. *Journal of Cell Science* 137(2): jcs261898. doi: 10.1242/jcs.261898
- Higo, S., Uematsu, M., Yamagishi, M., Ishibashi-Ueda, H., Awata, M., Morozumi, T.,

- Ohara, T., Nanto, S., & Nagata, S. 2005. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction. *Circulation Journal* 69(10): 1180–1185. doi:10.1253/circj.69.1180
- Hillis, G. S., Møller, J. E., Pellikka, P. A., Gersh, B. J., Wright, R. S., Ommen, S., Reeder, G. S., & Oh, J. K. 2004. Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. *Journal of the American College of Cardiology* 43(3): 360–367. doi:10.1016/j.jacc.2003.07.044
- Hoebers, L. P., Vis, M. M., Claessen, B. E., van der Schaaf, R. J., Kikkert, W. J., Baan, J., Jr., de Winter, R. J., Piek, J. J., Tijssen, J. G. P., Dangas, G. D., & Henriques, J. P. S. 2013. The impact of multivessel disease with and without a co-existing chronic total occlusion on short- and long-term mortality in ST-elevation myocardial infarction patients with and without cardiogenic shock. *European Journal Heart Failure* 15: 425–32. doi: 10.1093/eurjhf/hfs182
- Hopps, E., & Caimi, G. 2015. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. *European Review for Medical and Pharmacological Sciences* 19: 2583–2589
- Hu, W., Wei, R., Wang, L., Lu, J., Liu, H., & Zhang, W. 2017. Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events. *Experimental and Therapeutic Medicine* 15: 1994–2000. doi: 10.3892/etm.2017.5625
- Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.P., Crea, F., Goudevenos, J.A., Halvorsen, S., Hindricks, G., Kastrati, A., Lenzen, M.J., Prescott, E., Roffi, M., Valgimigli, M., Varenhorst, C., Vranckx, P., & Widimsky, P. 2018. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *European Heart Journal* 39(2): 119–177. doi: 10.1093/eurheartj/ehx393.
- Infante, T., Forte, E., Schiano, C., Scafuri, A., De Nigris, F., & Napoli, C. 2017. An integrated approach to coronary heart disease diagnosis and clinical management. *American Journal of Translational Research* 9(7): 3148
- Inokubo, Y., Hanada, H., Ishizaka, H., Fukushi, T., Kamada, T., & Okumura, K. 2001. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. *American Heart Journal* 141: 211–217.

- Ionac, I., Lazăr, M.-A., Brie, D. M., Erimescu, C., Vîă, R., & Mornoș, C. 2021. The incremental prognostic value of E/(e'×s') ratio in non-ST-segment elevated acute coronary syndrome. *Diagnostics* 11(8):1337.
- Ishida, M., Sakai, C., Kobayashi, Y., & Ishida, T. 2024. Cigarette smoking and atherosclerotic cardiovascular disease. *Journal of Atherosclerosis and Thrombosis* 31(3): 189–200. doi: 10.5551/jat.RV22015
- Jabatan Perangkaan Malaysia. 2023. *Statistics on causes of death*, Malaysia. Diperoleh daripada <https://www.dosm.gov.my/portal-main/release-content/statistics-on-causes-of-death-malaysia-2023>
- Jablonska-Trypuc, A., Matejczyk, M., & Rosochacki, S. 2016. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. *Journal of Enzyme Inhibition and Medicinal Chemistry* 31: 177–183. doi: 10.3109/14756366.2016.1161620
- Jackson, H. W., Defamie, V., Waterhouse, P., & Khokha, R. 2017. TIMPs: Versatile extracellular regulators in cancer. *Nature Reviews Cancer* 17: 38–53. doi: 10.1038/nrc.2016.115
- Jefferis, B. J., Whincup, P., Welsh, P., Wannamethee, G., Rumley, A., Lennon, L., Thomson, A., Lawlor, D., Carson, C., Ebrahim, S., & Lowe, G. 2010. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. *Atherosclerosis* 208: 557–563. doi: 10.1016/j.atherosclerosis.2009.08.018
- Jin, W., Yu, C., Wang, L., Zhao, Y., Kang, Y., Zhang, B., & Li, G. 2023. Abnormal inter-ventricular diastolic mechanical delay in patients with ST-segment elevation myocardial infarction. *BMC Cardiovascular Disorders* 23: 494. doi: 10.1186/s12872-023-03531-1
- Johnson, J. L. 2014. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: Current knowledge and clinical potential. *Metalloproteinase in Medicine* 1: 21–36.
- Johnson, J. L., Baker, A. H., Oka, K., Chan, L., Newby, A. C., Jackson, C. L., & George, S. J. 2006. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. *Circulation* 113: 2435–2444. doi: 10.1161/CIRCULATIONAHA.106.613281
- Jönsson, S., Lundberg, A., Kälvegren, H., Bergström, I., Szymanowski, A., & Jonasson,

- L. 2011. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. *PLOS ONE* 6(4): e19340. doi: 10.1371/journal.pone.0019340
- Kalamida, D., Poulas, K., Avramopoulou, V., Fostieri, E., Lagoumintzis, G., Lazaridis, K., Sideri, A., Zouridakis, M., & Tzartos, S. J. 2007. Muscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity. *The FEBS Journal* 274(15): 3799–3845. doi:10.1111/j.1742-4658.2007.05935.x
- Kamceva, G., Arsova-Sarafinovska, Z., Ruskovska, T., Zdravkovska, M., Kamceva-Panova, L., & Stikova, E. 2016. Cigarette Smoking and Oxidative Stress in Patients with Coronary Artery Disease. *Open Access Macedonian Journal of Medical Sciences* 4: 636–640
- Kandalam, V., Basu, R., Abraham, T., Wang, X., Awad, A., Wang, W., Lopaschuk, G. D., Maeda, N., Oudit, G. Y., & Kassiri, Z. 2010. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. *American Journal of Physiology – Heart and Circulatory Physiology* 299(4): H1012–H1023. doi: 10.1152/ajpheart.00246.2010
- Kapoor, C., Vaidya, S., Wadhwan, V., Kaur, G., & Pathak, A. 2016. Seesaw of matrix metalloproteinases (MMPs). *Journal of Cancer Research and Therapeutics* 12: 28–35. doi: 10.4103/0973-1482.157337
- Katzmarzyk, P. T., Friedenreich, C., Shiroma, E. J., & Lee, I. M. 2022. Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries. *British Journal of Sports Medicine* 56(2): 101–6.
- Kazemi, A., Soltani, S., Aune, D., Hosseini, E., Mokhtari, Z., Hassanzadeh, Z., Jayedi, A., Pitanga, F., & Akhlaghi, M. 2024. Leisure-time and occupational physical activity and risk of cardiovascular disease incidence: A systematic review and dose–response meta-analysis of prospective cohort studies. *International Journal of Behavioral Nutrition and Physical Activity* 21(1): 45. doi: 10.1186/s12966-024-01593-8
- Kelly, D., Cockerill, G., Ng, L. L., Thompson, M., Khan, S., Samani, N. J., & Squire, I. B. 2007. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: A prospective cohort study. *European Heart Journal* 28(6):711–718. doi:10.1093/eurheartj/ehm003
- Kementerian Kesehatan Malaysia. 2011. *Clinical Practice Guidelines: Management of Unstable Angina/ Non-ST Elevation Myocardial Infarction (UA/NSTEMI) (2nd edition)*.
Diperoleh daripada
<https://www.moh.gov.my/moh/resources/Penerbitan/CPG/CARDIOVASCULA>

R/12.pdf

Kementerian Kesihatan Malaysia. 2025. Laporan Tahunan Kementerian Kesihatan Malaysia 2024. Diperoleh daripada https://www.moh.gov.my/images/04-penerbitan/laporan-tahunan/Laporan_TahunanKKM2024.pdf

Kenawy, M. M., Saber, H. M., Al Akabawy, H. A. H., Muhammad, K. H., & Radwan, W. A. 2013. Role of tissue Doppler imaging in predicting left ventricular dysfunction after myocardial infarction. *The Egyptian Journal of Critical Care Medicine* 1(2): 87–94.

Khoi, P. N., Park, J. S., Kim, J. H., Xia, Y., Kim, N. H., Kim, K. K., & Jung, Y. D. 2013. Epigallocatechin-3-gallate blocks nicotine-induced matrix metalloproteinase-9 expression and invasiveness via suppression of NF- κ B and AP-1 in endothelial cells. *International Journal of Oncology* 43(3): 868–876. doi: 10.3892/ijo.2013.2006

Kim, J. Y., Mun, H. S., Lee, B. K., Yoon, S. B., Choi, E. Y., Min, P. K., Yoon, Y. W., Hong, B. K., Rim, S. J., & Kwon, H. M. 2010. Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. *Yonsei Medical Journal* 51(5): 676–682.

Kim, Y., Ahn, Y., Cho, M.C., Kim, C.J., Kim, Y.J., & Jeong, M.H. 2019. Current status of acute myocardial infarction in Korea. *Korean Journal International Medicine* 34: 1–10. doi: 10.3904/kjim.2018.381.

Kitulwatté, I. D., & Pollanen, M. S. 2015. A comparative study of coronary atherosclerosis in young and old. *The American Journal of Forensic Medicine and Pathology* 36(4): 323–326.

Knudtson, M. L. 2017. In search of the optimal strategy for multivessel disease revascularization. *JACC: Cardiovascular Interventions* 10(1): 24–26.

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R.F., Deaton, C., Cuisset, T., Agewall, S., Dickstein, K., Edvardsen, T., Escaned, J., Gersh, B.J., Svitil, P., Gilard, M., Hasdai, D., Hatala, R., Mahfoud, F., Masip, J., Muneretto, C., Valgimigli, M., Archenbach, S., & Bax, J.J. 2019. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). *European Heart Journal* 41: 407-77.

Kopych, V., Da Costa, A. D. S., & Park, K. 2025. Endothelial dysfunction in atherosclerosis: Experimental models and therapeutics. *Biomaterials Research*

29: 0252. doi: 10.34133/bmr.0252

Koskivirta, I., Rahkonen, O., Mayranpaa, M., Pakkanen, S., Husheem, M., Sainio, A., Hakovirta, H., Laine, J., Jokinen, E., Vuorio, E., Kovanen, P., & Jarvelainen, H. 2006. Tissue inhibitor of metalloproteinases-4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. *Histochemistry and Cell Biology* 126: 335–342. doi: 10.1007/s00418-006-0163-8

Kovacs, K. J. 2008. Measurement of Immediate-Early Gene Activation- c-fos and Beyond. *Journal of Neuroendocrinology* 20: 665–672. doi: 10.1111/j.1365-2826.2008.01734.x

Kraen, M., Frantz, S., Nihlén, U., Engström, G., Löfdahl, C.G., Wollmer, P., & Dencker, M., 2019. Matrix Metalloproteinases in COPD and atherosclerosis with emphasis on the effects of smoking. *PloS one* 14(2): p.e0211987.

Kremastiotis, G., Handa, I., Jackson, C., George, S., & Johnson, J. 2021. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. *Scientific Reports* 11(1): 23081. <https://doi.org/10.1038/s41598-021-02508-4>

Kuzniewska, B., Rejmak, E., Malik, A. R., Jaworski, J., Kaczmarek, L., & Kalita, K. 2013. Brain-derived neurotrophic factor induces matrix metalloproteinase-9 expression in neurons via the serum response factor/c-Fos pathway. *Molecular and Cellular Biology* 33(11): 2149–2162. doi: 10.1128/MCB.00008-13

Lahdentausta, L., Leskelä, J., Winkelmann, A., Tervahartiala, T., Sorsa, T., Pesonen, E., & Pussinen, P. J 2018. Serum MMP-9 diagnostics, prognostics, and activation in acute coronary syndrome and its recurrence. *Journal of Cardiovascular Translational Research* 11(3): 210–220. doi: 10.1007/s12265-018-9789-x

Lan, T. H., Huang, X. Q., & Tan, H. M. 2013. Vascular fibrosis in atherosclerosis. *Cardiovascular Pathology* 22(5):401–407. doi: 10.1016/j.carpath.2013.01.003

Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M. H., Rietzschel, E. R., Rudski, L., Spencer, K. T., Tsang, W., & Voigt, J.-U. 2015. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *European Heart Journal – Cardiovascular Imaging* 16(3): 233–271.

Laure, M., Hamza, H., Koch-Heier, J., Quernheim, M., Müller, C., Schreiber, A., Müller, G., Pleschka, S., Ludwig, S., & Planz, O. 2020. Antiviral efficacy against

- influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. *Antiviral Research* 178: 104806
- Lavine, S. J., & Kelvas, D. 2023. Diastolic dysfunction criteria and heart failure readmission in patients with heart failure and reduced ejection fraction. *The Open Cardiovascular Medicine Journal* 17. doi: 10.2174/18741924-v17-e230301-2022-9
- Layland, J. 2015. *Fractional Flow Reserve in Acute Coronary Syndrome*. Radcliffe Cardiology. Dipeeroleh daripada https://www.radcliffecardiology.com/articles/fractional-flow-reserve-acute-coronary-syndromes?language_content_entity=en
- Lee, A. M., Wu, D. F., Dadgar, J., Wang, D., McMahon, T., & Messing, R. O. 2015. PKC ϵ phosphorylates $\alpha 4\beta 2$ nicotinic ACh receptors and promotes recovery from desensitization. *British Journal of Pharmacology* 172(17): 4430-4441
- Lee, J., Adapala, R. K., Syed, I., & Sreejayan, N. 2002. Nicotine enhances proliferation of vascular smooth muscle cells through ERK1/2 and JNK pathways. *Journal of Applied Physiology* 92(1): 148–153. doi: 10.1152/jappphysiol.00471.2001
- Lee, S. H., Kim, J. H., Jeong, M. H., Ahn, Y. K., Chae, S. C., Kim, Y. J., Hur, S. H., Seong, I. W., Hong, T. J., Choi, D., Cho, M. C., Kim, C. J., Seung, K. B., Chung, W. S., Jang, Y. S., Cho, J. G., Park, J. C., Park, S. J. 2015. Clinical characteristics and outcomes of acute ST-segment elevation myocardial infarction in younger Korean adults. *Korean Circulation Journal* 45: 275–284. doi:10.4070/kcj.2015.45.4.275
- Lehoux, S., Lemarie, C. A., Esposito, B., Lijnen, H. R., & Tedgui, A. 2004. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. *Circulation* 109: 1041–1047.
- Lei, S., Liu, C., Zheng, T. X., Fu, W., & Huang, M. Z. 2024. The relationship of redox signaling with the risk for atherosclerosis. *Frontiers in Pharmacology* 15: 1430293.
- Lei, Z., Li, B., Li, B., & Peng, W. 2022. Predictors and prognostic impact of left ventricular ejection fraction trajectories in patients with ST-segment elevation myocardial infarction. *Aging Clinical and Experimental Research* 34(6): 1429-1438. doi: 10.1007/s40520-022-02087-y
- Leigh, A. J., Kaplan, R. C., Swett, K., Balfour, P., Kansal, M. M., Talavera, G. A., Ferreira, K., Blaha, M. J., Benjamin, E. J., Robertson, R., Bhartnagar, A., & Rodriguez, C. J. 2017. Smoking intensity and duration is associated with cardiac

structure and function: the ECHOCardiographic Study of Hispanics/Latinos. *British Medical Journals*. 4(2)

- Lenti, M., Falcinelli, E., Pompili, M., De Rango, P., Conti, V., Guglielmini, G., Momi, S., Corazzi, T., Giordano, G., & Gresele, P. 2014. Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. *Thrombosis and Haemostasis* 111(6): 1089-1101. doi: 10.1160/TH13-07-0588
- Li, C., Deng, C., Shi, D., & Zhao, R. 2024. Thin-cap fibroatheroma in acute coronary syndrome: Implication for intravascular imaging assessment. *International Journal of Cardiology* 405:131965
- Li, H., Yuan, Z., Li, S., Qi, Q., Liu, J., Zhou, M., Cai, J., Chen, A., Wang, Z., Ye, X., & Zhao, Q. 2017. Plasma levels of matrix metalloproteinase-9 in patients undergoing off-pump coronary artery bypass grafting. *Journal of Thoracic Disease* 9(4): 1006–1014. doi:10.21037/jtd.2017.03.156
- Li, S., Khoi, P. N., Yin, H., Sah, D. K., Kim, N. H., Lian, S., & Jung, Y. D. 2022. Sulforaphane suppresses the nicotine-induced expression of matrix metalloproteinase-9 via inhibiting ROS-mediated AP-1 and NF- κ B signaling in human gastric cancer cells. *International Journal of Molecular Sciences* 23(9): 5172. doi: 10.3390/ijms23095172
- Li, T., Li, X., Feng, Y., Dong, G., Wang, Y., & Yang, J. 2020. The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability. *Mediators Inflammation* 2020: 3872367. doi: 10.1155/2020/3872367
- Li, Y. T., Shen, W. Q., Duan, X., Li, Y., Wang, Y. X., Ren, X. X., Liu, Q. Q., Tian, J. W., & Du, G. Q. 2022. Left atrial strain predicts risk and prognosis in patients with acute coronary syndrome: A retrospective study with external validation. *Heliyon* 8: e11276. doi:10.1016/j.heliyon.2022.e11276
- Li, Y., Li, L., Wang, K., Wu, P., & Cui, Y. 2021. Investigation on risk stratification and the prognostic value of hs-TnT combined with MMP-2 in patients with acute coronary syndrome. *BioMed Research International* 2021: 1040171. doi: 10.1155/2021/1040171.
- Li, Y., Wang, R., Pan, X., Zhang, S., Wang, H., Liu, Z., & Zhao, X. 2023. Comprehensive analysis of autophagy-related gene expression in carotid atherosclerosis. *Orphanet Journal of Rare Diseases* 18(1): 1–15. doi: 10.1186/s13023-023-02660-2
- Li, Z. Z., Guo, Z. Z., Zhang, Z., Cao, Q. A., Zhu, Y. J., Yao, H. L., Wu, L. L., & Dai, Q. Y. 2015. Nicotine-induced upregulation of VCAM-1, MMP-2, and MMP-9

through the $\alpha 7$ -nAChR-JNK pathway in RAW264.7 and MOVAS cells. *Molecular and Cellular Biochemistry* 399(1–2): 49–58. doi: 10.1007/s11010-014-2231-z.

Life Technologies. 2011. RiboPure™-Blood Kit: Protocol (Part Number AM1928 Rev. D). Thermo Fisher Scientific. Diperoleh daripada <https://documents.thermofisher.com/TFS-Assets/LSG/manuals/1928MD.pdf>

Life Technologies. 2014. RNAlater tissue collection: RNA stabilization solution user guide (Cat. No. AM7020–AM7024). Thermo Fisher Scientific. Diperoleh daripada https://tools.thermofisher.com/content/sfs/manuals/cms_056069.pdf

Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., Amann, M., Anderson, H. R., Andrews, K. G., Aryee, M., Atkinson, C., Bacchus, L. J., Bahalim, A. N., Balakrishnan, K., Balmes, J., Barker-Collo, S., Baxter, A., Bell, M. L., Blore, J. D., Blyth, F., et al. 2012. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 380: 2224–2260

Lin, Y. T., Lin, Y. H., Wu, X. M., Ko, C. L., Yen, R. F., Chen, Y. H., Hsu, R. B., Lee, C. M., Wang, S. S., Chen, M. F., & Wu, Y. W. 2017. The relationship between serum fibrosis markers and restrictive ventricular filling in patients with heart failure with reduced ejection fraction: A technetium-99m radionuclide ventriculography study. *Oncotarget* 8(2): 2381–2390. doi: 10.18632/oncotarget.13795

Lindsey, M. L., Escobar, G. P., Dobrucki, L. W., Goshorn, D. K., Bouges, S., Mingoia, J. T., McClister, D. M., Su, H., Gannon, J., MacGillivray, C., Lee, R. T., Sinusas, A. J., & Spinale, F. G. 2006. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. *American Journal of Physiology – Heart and Circulatory Physiology* 290: H232–H240. doi:10.1152/ajpheart.00457.2005

Lindstrom, M., DeCleene, N., Dorsey, H., Fuster, V., Johnson, C.O., LeGrand, K.E., Mensah, G.A., Razo, C., Stark, B., Varieur, T.J., & Roth, G.A. 2022. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990–2021. *Journal of American College of Cardiology* 80(25): 2372–2425.

Linssen, P. B. C., Brunner-La Rocca, H. P., Schalkwijk, C. G., Beulens, J. W. J., Elders, P. J. M., van der Heijden, A. A., Sliker, R. C., Stehouwer, C. D. A., & Henry, R. M. A. 2020. Serum matrix metalloproteinases and left atrial remodeling: The Hoorn Study. *International Journal of Molecular Sciences* 21(14): 4944. doi:10.3390/ijms21144944

- Liu, J., Liu, Z., Zheng, E., Zhang, K., & Leng, J. 2017. The correlation of visfatin, MMP-9 and insulin resistance in patients with coronary heart disease. *International Journal of Clinical and Experimental Medicine* 10(3): 5278-5285
- Liu, L., Wu, H., Cao, Q., Guo, Z., Ren, A., & Dai, Q. 2017. Stimulation of alpha7 nicotinic acetylcholine receptor attenuates nicotine-induced upregulation of MMP, MCP-1, and RANTES through modulating ERK1/2/AP-1 signaling pathway in RAW264.7 and MOVAS cells. *Mediators of Inflammation* doi.org/10.1155/2017/2401027.
- Loftus, I. M., Naylor, A. R., Goodall, S., Crowther, M., Jones, L., Bell, P. R. F., & Thompson, M. M. 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: A potential role in acute plaque disruption. *Stroke* 31(1): 40–47. doi: 10.1161/01.STR.31.1.40
- Lopes, J., Adiguzel, E., Gu, S., Liu, S. L., Hou, G., Heximer, S., Assoian, R. K., & Bendeck, M. P. 2013. Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis. *American Journal of Pathology* 182: 2241–2253. doi: 10.1016/j.ajpath.2013.02.011
- Lv, X., Sun, J., Bi, Y., Xu, M., Lu, J., Zhao, L., & Xu, Y. 2015. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. *International Journal Cardiology* 199: 106–115
- López, B., Ravassa, S., Moreno, M. U., José, G. S., Beaumont, J., González, A., & Díez, J. 2021. Diffuse myocardial fibrosis: Mechanisms, diagnosis and therapeutic approaches. *Nature Reviews Cardiology* 18: 479–498. doi: 10.1038/s41569-020-00504-1
- Maas, S.C.E., Mens, M.M.J., Kühnel, B., van der Plaats, D.A., de Vries, M., Vonk, J.M., Nedeljkovic, I., Lahousse, L., de Jong, K., Postma, D.S., Gharib, S.A., Boezen, H.M. & van Diemen, C.C. 2020. Smoking-related changes in DNA methylation and gene expression are associated with cardio-metabolic traits. *Clinical Epigenetics* 12: 157.
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., et al. 2020. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European Heart Journal* 41(1): 111–188.
- Magna, A., Polisena, N., Polisena, L., Bagnato, C., Pacella, E., Carnevale, R., Nocella, C., & Loffredo, L. 2024. The Hidden Dangers: E-Cigarettes, Heated Tobacco, and Their Impact on Oxidative Stress and Atherosclerosis—A Systematic

Review and Narrative Synthesis of the Evidence. *Antioxidants* 13(11): 1395. doi: 10.3390/antiox13111395

Mancini, G.B., Gosselin, G., Chow, B., Kostuk, W., Stone, J., Yvorchuk, K.J., Abramson, B.L., Cartier, R., Huckell, V., Tardif, J.C., Connelly, K., Ducas, J., Farkouh, M.E., Gupta, M., Juneau, M., O'Neill, B., Raggi, P., Teo, K., Verma, S., & Zimmermann, R. 2014. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. *Canadian Journal Cardiology* 30(8):837-49

Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Coker, T. R., Davidson, K. W., Davis, E. M., Donahue, K. E., Jaén, C. R., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Ruiz, J. M., Stevermer, J., & Wong, J. B. 2022. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: US Preventive Services Task Force recommendation statement. *JAMA* 328(4):367–74. .

Martin-Vega, A., Cobb, M. H. 2023. Navigating the ERK1/2 MAPK Cascade. *Biomolecules* 13(10): 1555. doi: 10.3390/biom13101555

Martos, R., Baugh, J., Ledwidge, M., O'Loughlin, C., Conlon, C., Patle, A., Donnelly, S. C., & McDonald, K. 2007. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. *Circulation* 115(7): 888–95.

Marynenko, T., Halenova, T., Raksha, N., Vovk, T., Tyravska, Y., Savchuk, O., Falalyeyeva, T., Fagoonee, S., Abenavoli, & L., Ostapchenko, L. 2022. Plasma matrix metalloproteinases (MMP-2 and MMP-9) as prognostic biomarkers in coronary heart disease. *Minerva Biotechnology and Biomolecular Research* 34 (3): 137-42

Masoudkabir, F., Poorhosseini, H., Vasheghani-Farahani, A., Hakki, E., Roayaei, P., & Kassaian, S. E. 2015. Synergistic effect of hypertension with diabetes mellitus and gender on severity of coronary atherosclerosis: findings from Tehran Heart Center registry. *ARYA Atherosclerosis* 11(6): 317–322.

Masud, R., Shameer, K., Dhar, A., Killeen, K., Zubair, N., Michaelson, J., & Sengupta, P.P. 2012. Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease. *Journal of Clinical Bioinformatics* 2: 6.

Matos, L. C. V., Carvalho, L. S., Modolo, R., Santos, S., Almeida, O. L., & Sposito, A. C. 2021. Gensini score and thrombus burden add predictive value to the SYNTAX score in detecting no-reflow after myocardial infarction. *Arquivos*

Brasileiros de Cardiologia 116(3). doi: 10.36660/abc.20200045

Medina-Leyte, D. J., Zepeda-García, O., Domínguez-Pérez, M., González-Garrido, A., Villarreal-Molina, T., & Jacobo-Albavera, L. 2021. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. *International Journal of Molecular Science* 22(8):3850. doi: 10.3390/ijms22083850

Medley, T. L., Cole, T. J., Dart, A. M., Gatzka, C. D., & Kingwell, B. A. 2004. Matrix Metalloproteinase-9 Genotype Influences Large Artery Stiffness Through Effects on Aortic Gene and Protein Expression. *Arteriosclerosis, Thrombosis, and Vascular Biology* 24(8). doi: 10.1161/01.ATV.0000135656.49158.95

Merck KGaA. 2021. Histopaque-1077: Product information sheet (Catalog No. 10771). Sigma-Aldrich

Miao, G., Zhao, X., Chan, S. L., Zhang, L., Li, Y., Zhang, Y., Zhang, L., & Wang, B. 2022. Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis. *Metabolism* 132: 155213. doi: 10.1016/j.metabol.2022.155213

Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E. H., Voysey, M., Gray, A., Collins, R., & Baigent, C. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. *The Lancet* 380: 581–590.

Mishra, R. K., Devereux, R. B., Cohen, B. E., Whooley, M. A., & Schiller, N. B. 2011. Prediction of heart failure and adverse cardiovascular events in outpatients with coronary artery disease using mitral E/A ratio in conjunction with E-wave deceleration time: The Heart and Soul Study. *Journal of the American Society of Echocardiography* 24(10): 1134–1140.

Mitter, S. S., Shah, S. J., & Thomas, J. D. 2017. A test in context: E/A and E/e' to assess diastolic dysfunction and LV filling pressure. *Journal of the American College of Cardiology* 69(11): 1451–1464.

Mitter, S., Shah, S. J., & Thomas, J. D. 2017. A test in context: E/A and E/e' to assess diastolic dysfunction and LV filling pressure. *Journal of the American College of Cardiology* 69(11): 1451–1464.

Miyoshi, T., Doi, M., Hirohata, S., Sakane, K., Kamikawa, S., Kitawaki, T., Kaji, Y., Kusano, K. F., Ninomiya, Y., & Kusachi, S. 2010. Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. *Journal of*

Atherosclerosis and Thrombosis 17: 249–258.

- Mobasher, M., Hone, A. J., Pilzecker, M., Bozic, D., Hecker, A., McIntosh, J. M., Kirschner, K., Grau, V., Papke, R. L., Andleeb, H., & Richter, K. 2026. Putative $\alpha 1$ -selective ligands interact with $\alpha 9$ -containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytes. *Frontiers Immunology* doi: 10.3389/fimmu.2026.1773637
- Mouliou, D.S. 2023. C-reactive protein: Pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. *Diseases* 11(4): 132.
- Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C., & Blenis, J. 2002. Molecular interpretation of ERK signal duration by immediate early gene products. *Nature Cell Biology* 4: 556-564
- Myszko, M., Bychowski, J., Skryzdzewska, E., & Luczaj, W. 2025. The Dual Role of Oxidative Stress in Atherosclerosis and Coronary Artery Disease: Pathological Mechanisms and Diagnostic Potential. *Antioxidants* 14(3): 275. doi: 10.3390/antiox14030275
- Møller, J. E., Whalley, G. A., Dini, F. L., Doughty, R. N., Gamble, G. D., Klein, A. L., Quintana, M., & Yu, C. M. 2008. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: An individual patient meta-analysis. *Circulation* 117(20): 2591–2598. doi: 10.1161/CIRCULATIONAHA.107.738625
- Nabati, M., Golshani, S., Taghavi, M., Azizi, M., Razmi, M., Zolfaghari, M., & Ghajari, A. 2023. The association between tissue Doppler-derived E/(e's') ratio and coronary atherosclerosis severity measured by the SYNTAX score in patients with non-ST elevation acute coronary syndrome. *BMC Cardiovascular Disorders* 23: 98. doi: 10.1186/s12872-023-03128-8
- Nagase, H., Visse, R., & Murphy, G. 2006. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovascular Research* 69: 562–573. doi: 10.1016/j.cardiores.2005.12.002
- Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., Fayad, Z., Stone, P. H., Waxman, S., Raggi, P., Madjid, M., Zarrabi, A., Burke, A., Yuan, C., Fitzgerald, P. J., Siscovick, D. S., de Korte, C. L., Aikawa, M., Airaksinen, K. E. J., Assmann, G., Becker, C. R., Chesebro, J. H., Farb, A., Galis, Z. S., Jackson, C., Jang, I.-K., Koenig, W., Lodder, R. A., March, K., Demirovic, J., Navab, M., Priori, S. G., Reikhter, M. D., Bahr, R., Grundy, S. M., Mehran, R., Colombo, A., Boerwinkle, E., Ballantyne, C., Insull, W., Schwartz, R. S., Vogel, R., Serruys,

- P. W., Hansson, G. K., Faxon, D. P., Kaul, S., Drexler, H., Greenland, P., Muller, J. E., Virmani, R., Ridker, P. M., Zipes, D. P., Shah, P. K., & Willerson, J. T. 2003. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation* 108(15): 1772-1778
- Nagueh, S. F. 2020. Left ventricular diastolic function: Understanding pathophysiology, diagnosis, and prognosis with echocardiography. *JACC: Cardiovascular Imaging* 13(1 Part 2): 228–244.
- Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F. III, Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., Marino, P., Oh, J. K., Popescu, B. A., Waggoner, A. D. 2016. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography* 29(4): 277–314. doi: 10.1016/j.echo.2016.01.011
- Nath, D., Shivasekar, M., & Vinodhini, V. M. 2022. Smoking induces the circulating levels of matrix metalloproteinase-9 and its association with cardiovascular risk in young smokers. *Medeni Medical Journal* 37(4): 306–312. doi: 10.4274/MMJ.galenos.2022.45057.
- Neeland, I. J., Patel, R. S., Eshtehardi, P., Dhawan, S. S., McDaniel, M. C., Rab, S. T., Vaccarino, V., Zafari, A. M., Samady, H. & Quyyumi, A. A. 2012. Coronary angiographic scoring systems: An evaluation of their equivalence and validity. *American Heart Journal* 164(4): 547–552. doi: 10.1016/j.ahj.2012.07.007
- Newby, A. C. 2015. Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. *Matrix Biology* 44–46, 157–166. doi:10.1016/j.matbio.2015.01.015
- Newby, A. C. 2016. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. *Arteriosclerosis, Thrombosis, and Vascular Biology* 36(8), 1153-1163. doi :10.1161/ATVBAHA.115.306498
- Nielsen, S. H., Mouton, A. J., DeLeon-Pennell, K. Y., Genovese, F., Karsdal, M. A., & Lindsey, M. L. 2019. Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes. *Matrix Biology* 75-76: 43-57. doi: 10.1016/j.matbio.2017.12.001
- Nubila, A. D., Dilella, G., Simone, R., & Barbieri, S. S. 2024. Vascular extracellular matrix in atherosclerosis. *International Journal of Molecular Sciences* 25(22): 12017. doi: 10.3390/ijms252212017

- Nurkalem, Z., Hasdemir, H., Ergelen, M., Aksu, H., Guneyusu, T., & Seker, M. 2010. The relationship between glucose tolerance and severity of coronary artery disease using the Gensini score. *Angiology* 61(8): 751-755
- Ohara, T., & Little, W. C. 2010. Evolving focus on diastolic dysfunction in patients with coronary artery disease. *Current Opinion in Cardiology* 25(6): 613–621.
- Ojha, N., & Dhamoon, A. S. 2025. Myocardial infarction. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK537076/>
- Olejarz, W., Łacheta, D., & Kubiak-Tomaszewska, G. 2020. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. *International Journal of Molecular Sciences* 21(11), 3946. doi: 10.3390/ijms21113946
- Olvera, L, E., Ballard, B.D., & Jan, A. 2023. *Cardiovascular Disease*. StatPearls Publishing. Diperoleh daripada: <https://www.ncbi.nlm.nih.gov/books/NBK535419/>
- Osredkar, J., Bajrić, A., Možina, H., Lipar, L., & Jerin, A. 2024. Cardiac Troponins I and T as Biomarkers of Cardiomyocyte Injury—Advantages and Disadvantages of Each. *Applied Sciences* 14(14): 6007. doi: 10.3390/app14146007
- Otasević, P., Nesković, A. N., Popović, Z., Vlahović, A., Bojić, D., Bojić, M., & Popović, A. D. 2001. Short early filling deceleration time on day 1 after acute myocardial infarction is associated with short- and long-term left ventricular remodelling. *Heart* 85(5): 527–532. doi: 10.1136/heart.85.5.527.
- Owolabi, U. S., Amraotkar, A. R., Coulter, A. R., Singam, N. S. V., Aladili, B. N., Singh, A., Trainor, P. J., Mitra, R., & DeFilippis, A. P. 2020. Change in matrix metalloproteinase-2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. *Journal of Thrombosis and Thrombolysis* 49: 235–244. doi: 10.1007/s11239-019-02004-7
- Özkan, E., Celik, Y., Yucel-Lindberg, T., & Peker, Y. 2023. Current smoking determines the levels of circulating MPO and MMP-9 in adults with coronary artery disease and obstructive sleep apnea. *Journal of Clinical Medicine* 12(12): 4053. doi: 10.3390/jcm12124053.
- Palozza, P., Simone, R. E., Catalano, A., Saraceni, F., Celleno, L., Mele, M. C., Monego, G., & Cittadini, A. 2012. Modulation of MMP-9 pathway by lycopene in macrophages and fibroblasts exposed to cigarette smoke. *Inflammation & Allergy – Drug Targets* 11(1): 36–47. doi: 10.2174/1871528127988889376
- Papke, R.L. & Horenstein, N.A. 2021. Therapeutic targeting of $\alpha 7$ nicotinic acetylcholine receptors. *Pharmacological Reviews* 73(3): 1118–1149. doi:

10.1124/pharmrev.120.000097

- Paradies, V., Waldeyer, C., Laforgia, P. L., Clemmensen, P., & Smits, P. C. 2021. Completeness of revascularisation in acute coronary syndrome patients with multivessel disease. *EuroIntervention*. doi: 10.4244/EIJ-D-20-00957
- Parisi, V., Petraglia, L., Cabaro, S., D'Esposito, V., Bruzzese, D., Ferraro, G., Formisano, R., Marrone, G., Grimaldi, M.G., Paolillo, S., Iaconelli, A., Rengo, G. & Leosco, D. 2020. Imbalance between interleukin-1 β and interleukin-1 receptor antagonist in epicardial adipose tissue is associated with non-ST-segment elevation acute coronary syndrome. *Frontiers in Physiology* 11: 42. doi: 10.3389/fphys.2020.00042
- Park, J., Song, Y. J., Kim, S., Kim, D. K., Kim, K. H., Seol, S. H., Kim, D. I., & Ha, S. J. 2022. The long-term prognostic value of E/e' in patients with ST-segment elevation myocardial infarction. *Indian Heart Journal* 74(5): 369-374. doi: 10.1016/j.ihj.2022.08.002
- Park, W., Sung, S. C., & Hong, K. S. 2023. Impact of cigarette smoking and exercise on arterial stiffness: A narrative literature review. *Exercise Science* 32(2): 146–153. doi:10.15857/ksep.2023.00157
- PCR Biosystems. n.d. qPCRBIO SyGreen Mix Separate-ROX: Product Description and Protocol (Version 1.6). Retrieved from <https://pcrbio.com>
- Piątek-Matuszak, P., Paślawski, R., Paślawska, U., Kiczak, L., Płóciennik, M., Janiszewski, A., Michałek, M., Gwizdała, A., Kaźmierczak, J., & Gorący, J. 2022. Assessment of myocardial diastolic dysfunction as a result of myocardial infarction and extracellular matrix regulation disorders in the context of mesenchymal stem cell therapy. *Journal of Clinical Medicine* 11(18): 5430. doi:10.3390/jcm11185430
- Polonia, J., Barbosa, L., Silva, J. A., & Rosas, M. 2009. Improvement of aortic reflection wave responses 6 months after stopping smoking: A prospective study. *Blood Pressure Monitoring* 14(2): 69–75.
- Popov, M., Dabravolski, S., Dontsov, V., Vzvarov, S., Agafonov, E., Zybin, D., Radchenkova, O., Saveliev, D., Pronina, V., Kashirina, N., Lipatova, L., Peklo, M., Rutkevich, P., Yanushevskaya, E., Sokolovskaya, A., Metelkin, A., Verkhova, S., Nikiforov, N., & Shumakov, D. 2025. Prognostic Value of Matrix Metalloproteinase 9 (MMP9) in Patients Following Off-Pump Coronary Artery Bypass Grafting. *Life* 15(6): 908. doi: 10.3390/life15060908
- Poznyak, A., Grechko, A. V., Orekhova, V. A., Khotina, V., Ivanova, E. A., & Orekhov,

- A. N. 2020. NADPH oxidases and their role in atherosclerosis. *Biomedicines* 8(7): 206.
- Pramudyo, M., Jungjunan, R., Martanto, E., & Achmad, C. 2021. Correlation between MMP-9 level and diastolic dysfunction in concentric left ventricular hypertrophy patients. *International Journal of Integrated Health Sciences* 9(1): 1–6.
- Pugh, S. L., & Torres-Saavedra, P. A. 2021. Fundamental statistical concepts in clinical trials and diagnostic testing. *Journal of Nuclear Medicine* 62(6): 757–764. doi: 10.2967/jnumed.120.245654
- QIAGEN. 2018. RNeasy Lipid Tissue Mini Kit Handbook. Diperoleh daripada www.qiagen.com.my
- Qin, W., Zhang, L., Li, Z., Xiao, D., Zhang, Y., Zhang, H., Mokembo, J. N., Monayo, S. M., Jha, N. K., Kopylov, P., Shchekochikhin, D., & Zhang, Y. 2020. Endothelial to mesenchymal transition contributes to nicotine-induced atherosclerosis. *Theranostics* 10(12): 5276–5289. doi:10.7150/thno.42470
- Qiu, J., Liu, D., Li, P., Zhou, L., Zhou, L., Liu, X., Zhang, Y., Yuan, M., Tse, G., Li, G., & Liu, T. 2022. NADPH oxidase mediates oxidative stress and ventricular remodeling through SIRT3/FOXO3a pathway in diabetic mice. *Antioxidants (Basel)* 11(9): 1745. doi:10.3390/antiox11091745
- Radosinska, J., Barancik, M., & Vrbjar, N. 2017. Heart failure and role of circulating MMP-2 and MMP-9. *Panminerva Medicine* 59: 241–253. doi: 10.23736/S0031-0808.17.03321-3
- Rahman, M., Alatiqi, M., Al Jarallah, M., Hussain, M. Y., Monayem, A., Panduranga, P., & Rajan, R. 2025. Cardiovascular effects of smoking and smoking cessation: A 2024 update. *Global Heart* 20(1): 15. doi: 10.5334/gh.1399
- Ralapanawa, U., Kumarasiri, P.V.R., Jayawickreme, K.P., Kumarihamy, P., Wijeratne, Y., Ekanayake, M., Dissanayake, C. 2019. Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka. *BMC Cardiovascular Disorders*. 19(1): 229. doi: 10.1186/s12872-019-1217-x.
- Rampidis, G. P., Benetos, G., Benz, D. C., Giannopoulos, A. A., & Buechel, R. R. 2019. A guide for Gensini score calculation. *Atherosclerosis* 287: 181–183. doi: 10.1016/j.atherosclerosis.2019.05.012
- Ren, A., Wu, H., Liu, L., Guo, Z., Cao, Q., & Dai, Q. 2019. Nicotine promotes atherosclerosis development in apolipoprotein E-deficient mice through $\alpha 1$ -nAChR. *Journal of Cellular Physiology* 234(9): 14507–14518

- Robinson, S., Ring, L., Oxborough, D., Rana, B. S., Steeds, R., Harkness, A., Monaghan, M. J., & Robinson, K. 2024. The assessment of left ventricular diastolic function: Guidance and recommendations from the British Society of Echocardiography. *Echo Research & Practice* 11(1): 16.
- Roskoski, R. Jr. 2012. ERK1/2 MAP kinases: structure, function, and regulation. *Pharmacology Research* 66(2): 105-43. doi: 10.1016/j.phrs.2012.04.005.
- Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., Alam, K., Alla, F., Alvis-Guzman, N., Amrock, S., Ansari, H., Ärnlöv, J., Asayesh, H., Atey, T. M., Avila-Burgos, L., Awasthi, A., Banerjee, A., Barac, A., Bärnighausen, T., Barregard, L., Bedi, N., Belay Ketema, E., Bennett, D., Berhe, G., Bhutta, Z., Bitew, S., Carapetis, J., et al. 2017. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *Journal of the American College of Cardiology* 70(1): 1–25. doi: 10.1016/j.jacc.2017.04.052
- Saaoud, F., Shao, Y., Cornwell, W., Wang, H., Rogers, T. J., & Yang, X. 2023. Cigarette smoke modulates inflammation and immunity via reactive oxygen species-regulated trained immunity and trained tolerance mechanisms. *Antioxidants & Redox Signaling* 38(13–15): 1041–1069. doi: 10.1089/ars.2022.0087
- Sabry, M., Mostafa, S., Rashed, L., Abdelgwad, M., Kamar, S., & Estaphan, S. 2021. Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats. *PLoS One* 16(2): e0244650. doi: 10.1371/journal.pone.0244650
- Sadeghi, M., Khayati, S., Dehnavi, S., Almahmeed, W., Sukhorukovi, V. N., & Sahebkar, A. 2024. Regulatory impact of statins on macrophage polarization: mechanistic and therapeutic implications. *Journal of Pharmacy and Pharmacology* 76(7): 763–775.
- Sai, L., YanQiu, Z., DongMei, C., & YinJun, L. 2019. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. *Tropical Journal of Pharmaceutical Research* 18(3): 625–630. doi: 10.4314/tjpr.v18i3.26
- Salajegheh, A. 2016. Matrix metalloproteinase 2 (MMP2). *In Angiogenesis in Health, Disease and Malignancy* 261–266. doi: 10.1007/978-3-319-28140-7_31
- Salari, N., Morddarvanjoghi, F., Abdolmaleki, A., Rasoulpoor, S., Khaleghi, A. A., Hezarkhani, L. A., Shohaimi, S., & Mohammadi, M. 2023. The global prevalence of myocardial infarction: a systematic review and meta-

- analysis. *BMC Cardiovascular Disorders* 23(20). doi: 10.1186/s12872-023-03231-w
- Samah, N., & Ugusman, A., Hamid, A. A., Sulaiman, N., & Aminuddin, A. 2023. Role of Matrix Metalloproteinase-2 in the Development of Atherosclerosis among Patients with Coronary Artery Disease. *Mediators of Inflammation* 2023: 9715114. doi: 10.1155/2023/9715114
- Sanchis-Gomar, F., Perez-Quilis, C., Leischik, R., & Lucia, A. 2016. Epidemiology of coronary heart disease and acute coronary syndrome. *Annals of Translational Medicine* 4(13): 256.
- Sanyal, S., Amin, S. A., Banerjee, P., Gayen, S., & Jha, T. 2022. A review of MMP-2 structures and binding mode analysis of its inhibitors to strategize structure-based drug design. *Bioorganic & Medicinal Chemistry* 74: 117044. doi: 10.1016/j.bmc.2022.117044
- Sarwar, N., Gao, P., Seshasai, S. R., Gobin, R., Kaptoge, S., Di Angelantonio, E., Ingelsson, E., Lawlor, D. A., Selvin, E., Stampfer, M., Stehouwer, C. D., Lewington, S., Pennells, L., Thompson, A., Sattar, N., White, I. R., Ray, K. K., & Danesh, J. 2010. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. *The Lancet* 375: 2215–2222.
- Saxena, A., Chen, W., Su, Y., Rai, V., Uche, O. U., Li, N., & Frangogiannis, N. G. 2013. IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. *Journal of Immunology* 191(9): 4838-48. doi: 10.4049/jimmunol.1300725.
- Scatteia, A., Silverio, A., Padalino, R., De Stefano, F., America, R., Cappelletti, A. M., Dalla Vecchia, L. A., Guarini, P., Donatelli, F., & Caiazza, F., Dellegrottaglie, S. 2021. Non-invasive assessment of left ventricle ejection fraction: Where do we stand? *Journal of Personalized Medicine* 11(11): 1153. doi: 10.3390/jpm11111153.
- Serdar, C. C., Cihan, M., Yucel, D., & Serdar, M. A. 2021. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. *Biochemistry Medicine (Zagreb)* 31(1); 010502. doi: 10.11613/BM.2021.010502
- Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L. I., Netti, L., Montefusco, G., Chimenti, C., Lavalle, C., Maestrini, V., Mancone, M., Chilian, W. M., & Fedele, F. 2020. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. *International*

Journal of Molecular Sciences 21(21): 8118. doi: 10.3390/ijms21218118

Seyedian, S. M., Majididi, S., Asgharinejad, L., Esmaeli, M., Ahmadi, F., & Salehzadeh, M. 2015. Acute and chronic effect of cigarette on right and left ventricular diastolic function. *Jentashapir Journal of Cellular and Molecular Biology* 6(5): e25889. doi:10.17795/jjhr-25889

Shahjehan, R.D., Sharma, S., & Bhutta, B.S. 2024. Coronary Artery Disease. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK564304/>

Shams, P., Goyal, A., & Makaryus, A. N. 2025. Left ventricular ejection fraction. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK459131/>

Shang, W., Zhao, L. J., Dong, X., L., Zhao, Z. M., Li, J., Zhang, B. B., & Cai, H. 2016. Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways. *Molecular Medicine Reports* 14: 3620-3626

Sharafi, M., Dehghan, A., Mouseli, A., Fatemian, H., Jamali, L., Afrashteh, S., Chijan, M.R., Mastaneh, Z., Zakeri, A., & Alkamel, A. 2024. A cross-sectional study determining prevalence and factors associated with ST-segment elevation myocardial infarction and non-ST segment elevation myocardial infarction in Iran: results from fasa registry on acute myocardial infarction (FaRMI). *BMC Public Health* 24(728). doi: 10.1186/s12889-024-18140-6

Shi, X., & Qiu, H. 2020. Post-translational S-nitrosylation of proteins in regulating cardiac oxidative stress. *Antioxidants* 9(11): 1051. doi: 10.3390/antiox9111051

Silbiger, J. J. 2019. Pathophysiology and echocardiographic diagnosis of left ventricular diastolic dysfunction. *Journal of the American Society of Echocardiography* 32(2): 216–232.e2. doi: 10.1016/j.echo.2018.11.011

Silva, C.P. & Kamens, H.M. 2020. Cigarette smoke-induced alterations in blood: A review of research on DNA methylation and gene expression. *Experimental and Clinical Psychopharmacology* 29(1): 116–135. doi: 10.1037/pha0000382

Singh, A., Museedi, A. S., & Grossman, S. A. 2023. Acute coronary syndrome. StatPearls Publishing. Diperoleh daripada <https://pubmed.ncbi.nlm.nih.gov/29083796/>

Sinning, C., Lillpopp, L., Appelbaum, S., Ojeda, F., Zeller, T., Schnabel, R., Lubos, E., Kunde, J., Keller, T., Lackner, K. J., Münzel, T., & Blankenberg, S. 2013. Angiographic score assessment improves cardiovascular risk prediction: the

clinical value of SYNTAX and Gensini application. *Clinical Research in Cardiology* 102: 495–503.

Sivaraman, S. K., Zachariah, G., & Annamala, P. T. 2014. Effect of smoking on metalloproteinases (MMPs) activity in patients with acute myocardial infarction (AMI). *Journal of Clinical and Diagnostic Research* 8(2): 27–30

Sharma, A., Gupta, I., Venkatesh, U., Singh, A. K., Golamari, R., & Arya, P. 2023. E-cigarettes and myocardial infarction: A systematic review and meta-analysis. *International Journal of Cardiology* 371; 65-70. Doi: 10.1016/i.ij.card.2022.09.007

Song, X., Fu, Y., Li, C., Jia, Q., Ren, M., Zhang, X., Bie, H., Zhou, H., Gan, X., He, S., Wang, Y., Zhang, S., Pan, R., Sun, W., Zhou, H., Ni, Q., Song, J., Zhang, Q., Chen, X., & Jia, E. 2024. Single-cell RNA sequencing atlas of peripheral blood mononuclear cells from subjects with coronary artery disease. *Biochimica et Biophysica Acta (BBA) – Molecular Cell Research* 1871(1): 119593.

Spanò, D.P., & Scilabra, S.D. 2022. Tissue Inhibitor of Metalloproteases 3 (TIMP-3): In Vivo Analysis Underpins Its Role as a Master Regulator of Ectodomain Shedding. *Membranes (Basel)* 12(2): 211. doi: 10.3390/membranes12020211

Spinale, F. G., Coker, M. L., Heung, L. J., Bond, B. R., Gunasinghe, H. R., Etoh, T., Goldberg, A. T., Zellner, J. L., & Crumley, A. J. 2000. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. *Circulation* 102(16): 1944–1949. doi: 10.1161/01.cir.102.16.1944.

Stöhr, R., Cavalera, M., Menini, S., Mavilio, M., Casagrande, V., Rossi, C., Urbani, A., Cardellini, M., Pugliese, G., Menghini, R., & Federici, M. 2014. Loss of TIMP-3 exacerbates atherosclerosis in ApoE-null mice. *Atherosclerosis* 235(2): 438–443.

Sun, Y., Liu, W. Z., Liu, T., Feng, X., Yang, N., & Zhou, H. F. 2015. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. *Journal of Receptors and Signal Transduction Research* 35(6): 600-4. doi: 10.3109/10799893.2015.1030412.

Supriami, K., Urbut, S. M., Tello-Ayala, J. R., Unlu, O., Friedman, S. F., Abou-Karam, R., Koyama, S., Uddin, M. M., Pomerantsev, E., Lu, M. T., Honigberg, M. C., Aragam, K. G., Doshi-Velez, F., Patel, A. P., Natarajan, P., Ellinor, P. T., & Fahed, A. C. 2025. Genomic drivers of coronary artery disease and risk of future outcomes after coronary angiography. *JAMA Network Open* 8(1): e2455368. doi:10.1001/jamanetworkopen.2024.55368

- Swarup, S., Patibandla, S., & Grossman, S.A. 2023. Coronary Artery Vasospasm. StatPearls Publishing. Diperoleh daripada <https://www.ncbi.nlm.nih.gov/books/NBK470181/>
- Sweis, R. N., & Jivan, A. 2024. *Overview of acute coronary syndromes (ACS)*. In Merck Manual Professional Edition. Merck & Co., Inc. Diperoleh daripada https://www.merckmanuals.com/professional/cardiovascular-disorders/coronary-artery-disease/overview-of-acute-coronary-syndromes-ac#Symptoms-and-Signs_v934825
- Tai, S. B., Lau, W. R., Gao, F., Hamid, N., Amanullah, M. R., Fam, J. M., Yap, J., Ewe, S. H., Chan, M. Y., Yeo, K. K., Ding, Z. P., & Sahlén, A. 2020. E/e' in relation to outcomes in ST-elevation myocardial infarction. *Echocardiography* 37(4): 554–560. doi: 10.1111/echo.14652
- Takawale, A., Sakamuri, S. S. V. P., & Kassiri, Z. 2015. Extracellular matrix communication and turnover in cardiac physiology and pathology. *Comprehensive Physiology* 5(2): 687–719. Doi: 10.1002/cphy.c140045
- Takawale, A., Zhang, P., Azad, A., Wang, W., Wang, X., Murray, A. G., & Kassiri, Z. 2017. Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis. *American Journal of Physiology – Heart and Circulatory Physiology* 313: H224–H236. doi: 10.1152/ajpheart.00108.2017
- Tamis-Holland, J. E., Jneid, H., Reynolds, H. R., Agewall, S., Brilakis, E. S., Brown, T. M., Lerman, A., Cushman, M., Kumbhani, D. J., Arslanian-Engoren, C., Bolger, A. F., & Beltrame, J. F. 2019. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: A scientific statement from the American Heart Association. *Circulation* 139(18): e891–e908. doi: 10.1161/CIR.0000000000000670
- Tanase, D. M., Valasciuc, E., Anton, I.-B., Gosav, E. M., Dima, N., Cucu, A. I., Costea, C. F., Floria, D. E., Hurjui, L. L., Tarniceriu, C. C., Ciocoiu, M., & Floria, M. 2025. Matrix metalloproteinases: Pathophysiologic implications and potential therapeutic targets in cardiovascular disease. *Biomolecules* 15(4): 598.
- Tanindi, A., Sahinarslan, A., Elbeg, S., & Cemri, M. 2011. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease. *Open Cardiovascular Medicine Journal* 5: 110–116. doi: 10.2174/1874192401105010110
- Tansawet, A., Anothaisintawee, T., Boonmanunt, S. W., Pornsuriyasak, P., Sukhato, K., Chawala, N., Inpithuk, P., Savigamin, C., Liampeng, S., Attia, J., McKay, G.

- J., Thakkestian, A. 2025. Electronic cigarettes and cardiovascular diseases: An updated systematic review and network meta-analysis. *Tobacco Induced Diseases* 23. doi: 10.18332/tid/208065.
- Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey, S. G., Ward, K., & Ebrahim, S. 2013. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Systematic Review* 2013(1). doi: 10.1002/14651858.
- Teresa, G., Claudio, S., Youssef, S.A., Denitsa, M., Christopher, W., Philip, S., Aslihan, E., Lukas, Z., Gregor N., Johanna, M., Lara, S., Barbara, E. S., Rocco, A. M., Rocco, V., Arash, H., Carsten, S., Fabian K., Henryk, D., Tobias, D. T., Himanshu, R., Michael, J., Jens, K., Peter, L., Filipino, C., Nicolle, K., Ulf, L., & David, M. L. 2023. Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome. *European Heart Journal* 44 (38): 3911–3925. doi: 10.1093/eurheartj/ehad334
- Theofilis P, Oikonomou E, Chasikidis C, Tsioufis K, Tousoulis D. 2023. Pathophysiology of Acute Coronary Syndromes-Diagnostic and Treatment Considerations. *Life (Basel)*. 13(7):1543. doi: 10.3390/life13071543.
- Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A. S., Lazaros, G., Theofilis, A., Papastamos, C., Papaioannou, S., Siasos, G., Tsioufis, K., & Tousoulis, D. 2022. Extracellular matrix remodeling biomarkers in coronary artery disease. *Current Topics in Medicinal Chemistry* 22(28): 2355–2367. doi: 10.2174/1568026623666221024091758
- Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. 2018. Fourth universal definition of myocardial infarction (2018). *Circulation* 138 (20). doi: 10.1161/CIR.0000000000000617
- Towhid, S. A. A., Yousuf, T. B., & Begum, R. A. 2023. Effect of Smoking on Red Blood Cell Parameters: A Cross-sectional Study in a Divisional City of Bangladesh. *Journal of Monno Medical College* 9(2):41-46
- U.S Department of Health and Human Services. 2014. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta: U.S. Diperoleh daripada https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf
- Van den Brink, G. R., O'Toole, T., Hardwick, J. C., Van den Boogaardt, D. E.,

- Versteeg, H. H., Van Deventer, S. J., & Peppelenbosch, M. P. 2000. Leptin signaling in human peripheral blood mononuclear cells: Activation of p38 and p42/44 mitogen-activated protein kinase and p70 S6 kinase. *Molecular and Cellular Biology Research Communications* 4: 144–150. doi: 10.1006/mcbr.2001.0270
- Vazquez-Padron, R.I., Mateu, D., Rodriguez-Menocal, L., Wei, Y., Webster, K.A. & Pham, S.M. 2010. Novel role of Egr-1 in nicotine-related neointimal formation. *Cardiovascular Research* 88: 296–303. doi: 10.1093/cvr/cvq213
- Versteyleen, M. O., Joosen, I. A., Shaw, L. J., Narula, J., & Hofstra, L. 2011. Comparison of Framingham, PROCAM, SCORE, and Diamond-Forrester to predict coronary atherosclerosis and cardiovascular events. *Journal of Nuclear Cardiology* 18: 904–911.
- Vieira-Alves, I., Coimbra-Campos, L. M. C., Sancho, M., da Silva, R. F., Cortes, S. F., & Lemos, V. S. 2020. Role of the $\alpha 7$ nicotinic acetylcholine receptor in the pathophysiology of atherosclerosis. *Frontiers in Physiology* 11: 621769. doi: 10.3389/fphys.2020.621769
- Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, T., Di Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., Jankowska, E. A., Michal, M., Sacco, S., Sattar, N., Tokgozoglu, L., Tonstad, S., Tsioufis, K. P., van Dis, I., van Gelder, I. C., Wanner, C., & Williams, B. 2021. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal* 42(34): 3227–3337. doi: 10.1093/eurheartj/ehab484.
- Vivantis Technologies. 2017. Viva cDNA Synthesis Kit: Product Datasheet (Product No. cDSK01-050). Retrieved from <https://www.vivanttechnologies.com>
- Volkov, A.M., Murashov, I.S., Polonskaya, Y.V., Savchenko, S.V., Kazanskaya, G.M., Kliver, E.E., Ragino, Y.I., & Chernyavskiy, A.M. 2018. Changes of content of matrix metalloproteinases and their tissue expression in various types of atherosclerotic plaques. *Kardiologiia*. 17(10): 12–18. doi: 10.18087/cardio.2018.10.10180.
- Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., Chieffo, A., Christodorescu, R. M., Deaton, C., Doenst, T., Jones, H. W., Kunadian, V., Mehilli, J., Milojevic, M., Piek, J. J., Pugliese, F., Rubboli, A., Semb, A. G., Senior, R., Ten Berg, J. M., Van Belle, E., Van Craenenbroeck, E. M., Vidal-Perez, R., & Winther, S. 2024. 2024 ESC guidelines for the management of

chronic coronary syndromes. *European Heart Journal* 45(36): 3415–3537

Wald, D. S., Morris, J. K., Wald, N. J., Chase, A. J., Edwards, R. J., Hughes, L. O., Berry, C., Oldroyd, K. G., & PRAMI Investigators. 2013. Randomized trial of preventive angioplasty in myocardial infarction. *New England Journal of Medicine* 369(12): 1115–1123. doi: 10.1056/NEJMoa1305520

Wan Ahmad, W. A. 2024. *Annual Report of the NCD-ACS Registry, 2020-2021*. National Cardiovascular Disease Database. Kuala Lumpur, Malaysia.

Wang, H., Liu, Z., Shao, J., Lin, L., Jiang, M., Wang, L., Lu, X., Zhang, H., Chen, Y., & Zhang, R. 2020. Immune and inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. *Journal of Immunology Research* 2020(1): 4904217. doi: 10.1155/2020/4901217

Wang, J., Tan, G. J., Han, L. N., Bai, Y. Y., He, M., & Liu, H. B. 2017. Novel biomarkers for cardiovascular risk prediction. *Journal of Geriatric Cardiology* 14: 135–150.

Wang, X., & Ji, X. 2020. Sample Size Estimation in Clinical Research From Randomized Controlled Trials to Observational Studies. *Chest* 158(1S): S12–S20. doi: 10.1016/j.chest.2020.03.010

Wang, X., & Khalil, R. A. 2018. Matrix metalloproteinases, vascular remodeling, and vascular disease. *Advances in Pharmacology* 81, 241–330. doi: 10.1016/bs.apha.2017.08.002

Wang, Y., Lv, Q., Li, Y., Chen, S., Zhao, L., Fu, G., & Zhang, W. 2022. Gensini score values for predicting periprocedural myocardial infarction: An observational study analysis. *Medicine* 101(29): e29491. doi: 10.1097/MD.00000000000029491

Watanabe, R., Maeda, T., Zhang, H., Berry, G. J., Zeisbrich, M., Brockett, R., Greenstein, A. E., Tian, L., Goronzy, J. J., & Weyand, C. M. 2018. MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis. *Circ Res.* 2018 Aug 31;123(6):700-715. doi: 10.1161/CIRCRESAHA.118.313206

Webb, C. S., Bonnema, D. D., Ahmed, S. H., Leonardi, A. H., McClure, C. D., Clark, L. L., Stroud, R. E., Corn, W. C., Finklea, L., Zile, M. R., & Spinale, F. G. 2006. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. *Circulation* 114: 1020–1027. doi: 10.1161/circulationaha.105.600353

Webster, N. L., & Crowe, J. S. 2006. Matrix metalloproteinases, their production by

- monocytes and macrophages. *Journal of Leukocyte Biology* 80(4): 677–685.
- Westman, P. C., Lipinski, M. J., Luger, D., Waksman, R., Bonow, R. O., Wu, E., & Epstein, S. E. 2016. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. *Journal of the American College of Cardiology* 67(17): 2050-60. doi: 10.1016/j.jacc.2016.01.073
- Wewege, M. A., Thom, J. M., Rye, K.-A., & Parmenter, B. J. 2018. Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome. *Atherosclerosis* 274: 162–171. doi: 10.1016/j.atherosclerosis.2018.05.002
- Whitehead, A.K., Erwin, A.P. & Yue, X. 2021. Nicotine and vascular dysfunction. *Acta Physiologica* 231(4): e13631. doi: 10.1111/apha.13631
- Widimsky, P., Wijns, W., Fajadet, J., de Belder, M., Knot, J., Aaberge, L., Andrikopoulos, G., Baz, J. A., Betriu, A., Claeys, M., Danchin, N., Djambazov, S., Erne, P., Hartikainen, J., Huber, K., Kala, P., Klinceva, M., Kristensen, S. D., Ludman, P., Mauri Ferre, J., Merkely, B., Milicic, D., Morais, J., Noc, M., Opolski, G., Ostojic, M., Radovanovic, D., De Servi, S., Stenestrand, U., Studencan, M., Tubaro, M., Vasiljevic, Z., Weidinger, F., Witkowski, A., & Zeymer, U. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *European Heart Journal* 31(8): 943-957. doi: 10.1093/eurheartj/ehp492
- Wingrove, J.A., Daniels, S.E., Sehnert, A.J., Tingley, W., Elashoff, M.R., Rosenberg, S., Buellesfeld, L., Grube, E., Newby, L.K., Ginsburg, G.S., & Kraus, W.E. 2008. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. *Circulation: Cardiovascular Genetics* 1: 31–38. doi: 10.1161/CIRCGENETICS.108.782730
- Wolosowicz, M., Prokopiuk, S., & Kaminski, T. W. 2024. The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease. *International Journal of Molecular Sciences* 25(24): 13691. doi:10.3390/ijms252413691
- World Health Organization. 2025. *Cardiovascular diseases (CVDs) WHO News-room: fact sheets*. Diperoleh daripada [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
- World Health Organization. 2025. *WHO global report on tobacco*. Diperoleh daripada <https://www.who.int/news-room/fact-sheets/detail/tobacco>
- Wu, A. D., Lindson, N., Hartmann-Boyce, J., Wahedi, A., Hajizadeh, A., Theodoulou, A., Thomas, E. T., Lee, C., & Aveyard, P. 2022. Smoking cessation for

- secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 8(8): CD014936. doi: 10.1002/14651858.CD014936.pub2
- Wu, D., Yuan, Y., Lin, Z., Lai, T., Chen, M., Li, W., Lv, Q., Yuan, B., Li, D., & Wu, B. 2016. Cigarette smoke extract induces placental growth factor release from human bronchial epithelial cells via ROS/MAPK (ERK-1/2)/Egr-1 axis. *International Journal of Chronic Obstructive Pulmonary Disease* 11: 3031–3042. doi: 10.2147/COPD.S120849.
- Wu, H., Shou, X., Liang, L., Wang, C., Yao, X., & Cheng, G. 2016. Correlation between plasma angiopoietin-1, angiopoietin-2 and matrix metalloproteinase-2 in coronary heart disease. *Archives of Medical Science* 12(6): 1214-1219. doi: 10.5114/aoms.2016.62909.
- Xie, Y. T., Dang, Y., Zhang, F. F., Zhang, Q. H., Wu, H. B., & Liu, G. 2020. Combination of serum TIMP-3, CA125, and NT-proBNP in predicting ventricular remodeling in patients with heart failure following acute myocardial infarction. *Cardiovascular Diagnosis & Therapy* 10(5): 1184–1191. doi: 10.21037/cdt-20-399.
- Xu, S., Ni, H., Chen, H., & Dai, Q. 2019. The interaction between STAT3 and nAChR α 1 interferes with nicotine-induced atherosclerosis via Akt/mTOR signaling cascade. *Aging* 11(19): 8120-8138. doi: 10.18632/aging.102296.
- Yabluchanskiy, A., Ma, Y., Iyer, R. P., Ho, W., Jin, Y.-F., & Lindsey, M. L. 2013. Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular Remodeling. *Frontiers in Physiology* 4: 370. <https://doi.org/10.3389/fphys.2013.00370>
- Yahud, E., Tzuman, O., Fink, N., Goldenberg, I., Goldkorn, R., Peled, Y., Lev, E., & Asher, E. 2020. Trends in long-term prognosis according to left ventricular ejection fraction after acute coronary syndrome. *Journal of Cardiology* 76: 303–308.
- Yang, D., Liu, X., & Xiang, M. 2011. The correlation between lipid ratios and degree of coronary artery stenosis. *High Blood Pressure & Cardiovascular Prevention* 18(2): 53–56. doi: 10.2165/11593480-000000000-00000.
- Yang, C., Li, Z., Yan, S., He, Y., Dai, R., Leung, G. P., Pan, S., Yang, J., Yan, R., & Du, G. 2016. Role of the nicotinic acetylcholine receptor α 3 subtype in vascular inflammation. *British Journal of Pharmacology* 173(22):3235-3247. doi: 10.1111/bph.13609
- Yang, X., Li, Y., Li, Y., Ren, X., Zhang, X., Hu, D., Gao, Y., Xing, Y., & Shang, H. 2017. Oxidative stress-mediated atherosclerosis: mechanisms and therapies.

Frontiers in Physiology 8: 600. doi: 10.3389/fphys.2017.00600

Yang, Y., Li, G., & Zhang, R. 2022. Correlation analysis of acute coronary syndrome with serum IL-18, MMP-9, hs-CRP, and plasma fibrinogen. *BioMed Research International* 2022: 5984184. doi: 10.1155/2022/5984184.

Yano, M., Miura, S., Shiga, Y., Miyase, Y., Suematsu, Y., Norimatsu, K., Nakamura, A., Adachi, S., Nishikawa, H., & Saku, K. 2016. Association between smoking habits and severity of coronary stenosis as assessed by coronary computed tomography angiography. *Heart and Vessels* 31(7): 1061–1068. doi: 10.1007/s00380-015-0716-7

Yu, J., Pan, W., Yang, T., Zhang, G., & Shi, R. 2012. Relationship between Sphingomyelinase, Ceramide, and Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease. *Heart* 98(2). doi: 10.1136/heartjn1-2012-302920j.52.

Zawadka, M., Marchel, M., & Andruszkiewicz, P. 2020. Diastolic dysfunction of the left ventricle – a practical approach for an anaesthetist. *Anaesthesiology Intensive Therapy* 52(3): 237–244. doi:10.5114/ait.2020.94486

Zeller, T., Seiffert, M., Müller, C., Scholz, M., Schäffer, A., Ojeda, F., Drexel, H., Mündlein, A., Kleber, M. E., März, W., Sinning, C., Brunner, F. J., Waldeyer, C., Keller, T., Saely, C. H., Sydow, K., Thiery, J., Teupser, D., Blankenberg, S., & Schnabel, R. 2017. Genome-wide association analysis for severity of coronary artery disease using the Gensini scoring system. *Frontiers in Cardiovascular Medicine* 4: 57. doi: 10.3389/fcvm.2017.00057

Zhang, P., Hou, M., Li, Y., Xu, X., Barsoum, M., Chen, Y., & Bache, R. J. 2009. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. *American Journal of Physiology – Heart and Circulatory Physiology* 296: H840–H846. doi:10.1152/ajpheart.00519.2008

Zhang, R., Bu, F., Wang, Y., Huang, M., Lin, X., Wu, C., Chen, J., Huang, Y., Wang, H., Ye, S., Hu, X., Wang, Q., & Zheng, L. 2023. LncRNA RP4-639F20.1 interacts with THRAP3 to attenuate atherosclerosis by regulating c-FOS in vascular smooth muscle cells proliferation and migration. *Atherosclerosis* 379: 117183

Zhang, W., Guo, Z., Li, L., Shi, Z., & Zhu, T. 2022. Hypoxia Promotes Human Umbilical Vein Smooth Muscle Cell Phenotypic Switching via the ERK 1/2/c-fos/NF-κB Signaling Pathway. *Annals of Vascular Surgery* 84: 371–380.

Zhang, X., Li, K., Cardoso, C., Moctezuma-Ramirez, A., & Elgalad, A. 2024.

Interpreting diastolic dynamics and evaluation through echocardiography. *Life* 14(9): 1156. doi:10.3390/life14091156

Zhang, Y., Zhang, W., Edvinsson, L. & Xu, C.B. 2017. Lipid-soluble cigarette smoke particles induced vascular endothelin type A receptor upregulation through activation of ERK1/2 signal pathways. *Basic & Clinical Pharmacology & Toxicology* 120: 327–334. doi: 10.1111/bcpt.12688
 Zhou, J., Zhang, J., & Chao, J. 2012. Porphyromonas gingivalis promotes monocyte migration by activating MMP-9. *J Periodontal Res.* 2012 Apr;47(2):236-42. doi: 10.1111/j.1600-0765.2011.01427.x.

Zhao, X., Chen, J., Sun, H., Zhang, Y., & Zou, D. 2022. New insights into fibrosis from the ECM degradation perspective: the macrophage–MMP–ECM interaction. *Cell & Bioscience* 12: 117. doi: 10.1186/s13578-022-00856-w

Zymo Research. 2023. Quick-RNA Miniprep Kit: Instruction manual (Version 4.1.4). Diperoleh daripada <https://www.zymoresearch.com>

